

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/003917

International filing date: 04 February 2005 (04.02.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/542,098
Filing date: 04 February 2004 (04.02.2004)

Date of receipt at the International Bureau: 07 April 2005 (07.04.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1300902

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

April 01, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/542,098

FILING DATE: February 04, 2004

RELATED PCT APPLICATION NUMBER: PCT/US05/03917



Certified by

Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR §1.53(c).

| INVENTOR(S) | | | | | |
|---|------------------------|---|--|-----------|--|
| Given Name (first and middle [if any]) | Family Name or Surname | Residence (City and either State or Foreign Country) | | | |
| Jing X. | Kang | North Andover, MA | | | |
| Additional inventors are being named on the <u>0</u> separately numbered sheets attached hereto | | | | | |
| TITLE OF THE INVENTION (500 characters max) | | | | | |
| MODIFIED FAT-1 NUCLEIC ACIDS, COMPOSITIONS AND METHODS FOR MODIFYING THE CONTENT OF POLYUNSATURATED FATTY ACIDS IN MAMMALIAN CELLS | | | | | |
| CORRESPONDENCE ADDRESS | | | | | |
| Direct all correspondence to: | | | | | |
| [X] Customer Number: 26161 | | | | | |
| OR | | | | | |
| [] Firm or Individual Name | | | | | |
| Address | | | | | |
| Address | | | | | |
| City | | State | | ZIP | |
| Country | | United States | | Telephone | |
| | | | | Fax | |
| ENCLOSED APPLICATION PARTS (check all that apply) | | | | | |
| [X] Specification | | Number of Pages | | 44 | |
| [] CD(s), Number | | | | | |
| [X] Drawing(s) | | Number of Sheets | | 20 | |
| [] Other (specify) | | | | | |
| [] Application Data Sheet. See 37 CFR 1.76. | | | | | |
| METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT | | | | | |
| [] Applicant Claims small entity status. See 37 CFR 1.27. | | | | | |
| [X] A check or money order is enclosed to cover the filing fees. | | | | | |
| [] The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: | | | | | |
| | | | | 06-1050 | |
| [] Payment by credit card. Form PTO-2038 is attached. | | | | | |
| The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government. | | | | | |
| [] No. | | | | | |
| [X] Yes, the name of the U.S. Government agency and the Government contract number are: | | | | | |
| National Institutes of Health, CA79553 | | | | | |

Respectfully submitted,

Signature

Typed Name Lee Crews, Ph.D., Reg. No. 43,567Telephone No. (617) 542-5070Docket No. 00786-815P01

20800735.doc

CERTIFICATE OF MAILING BY EXPRESS MAILExpress Mail Label No. EL964756698USDate of Deposit February 4, 200417354 U.S. PTO
60/542098

020404

PROVISIONAL APPLICATION FOR PATENT

under

37 CFR §1.53(c)

TITLE: MODIFIED FAT-1 NUCLEIC ACIDS, COMPOSITIONS
AND METHODS FOR MODIFYING THE CONTENT OF
POLYUNSATURATED FATTY ACIDS IN MAMMALIAN
CELLS

APPLICANT: JING X. KANG

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EL964756698US

Date of Deposit February 4, 2004

MODIFIED FAT-1 NUCLEIC ACIDS, COMPOSITIONS AND METHODS FOR MODIFYING THE CONTENT OF POLYUNSATURATED FATTY ACIDS IN MAMMALIAN CELLS

TECHNICAL FIELD

This invention relates to compositions and methods for altering the content of polyunsaturated fatty acids in mammalian cells.

BACKGROUND

Some of the work presented herein was supported by a grant from the National Institutes of Health (CA79553). The United States government may, therefore, have certain rights in the invention.

Polyunsaturated fatty acids (PUFAs) are fatty acids having 18 or more carbon atoms and two or more double bonds. They can be classified into two groups, n-6 or n-3, depending on the position (n) of the double bond nearest the methyl end of the fatty acid (Gill and Valivety, *Trends Biotechnol.* 15:401-409, 1997; Broun *et al.*, *Annu. Rev. Nutr.* 19:197-216, 1999; Napier *et al.*, *Curr. Opin. Plant Biol.* 2:123-127, 1999). The n-6 and n-3 PUFAs are synthesized through an alternating series of desaturations and elongations beginning with either linoleic acid (LA, 18:2n6) or α -linolenic acid (ALA, 18:3n3), respectively (Gill and Valivety, *supra*; Broun *et al.*, *supra*; Napier *et al.*, *supra*). The major end point of the n-6 pathway in mammals is arachidonic acid (AA, 20:4n6) and major end points of the n-3 pathway are eicosapentaenoic acid (EPA, 20:5n3) and docosahexaenoic acid (DHA, 22:6n3).

An important class of enzymes involved in the synthesis of PUFAs is the class of fatty acid desaturases. These enzymes introduce double bonds into the hydrocarbon chain at positions determined by the enzyme's specificity. Although, in most cases, animals contain the enzymatic activity to convert LA (18:2n6) and ALA (18:3n3) to longer-chain PUFA (where the rate of conversion is limiting), they lack the 12- and 15-desaturase activities necessary to synthesize the precursor (parent) PUFA, LA and ALA (Knutzon *et al.*, *J. Biol. Chem.* 273:29360-29366, 1998). Furthermore, the n-3 and n-6 PUFA are not interconvertible in mammalian cells (Goodnight *et al.*, *Blood* 58: 880-885, 1981). Thus, both LA and ALA and their elongation, desaturation products are

considered essential fatty acids in the human diet. The PUFA composition of mammalian cell membranes is, to a great extent, dependent on dietary intake (Clandinin *et al.*, *Can. J. Physiol. Pharmacol.* 63:546-556, 1985; McLennan *et al.*, *Am. Heart J.* 116:709-717, 1988).

To the contrary, some plants and microorganisms are able to synthesize n-3 fatty acids such as ALA (18:3n-3) because they have membrane-bound 12- and 15- (n-3) desaturases that act on glycerolipid substrates in both the plastid and endoplasmic reticulum (Browse and Somerville, *Annu. Rev. Plant Physiol. Plant Mol. Biol.* 42: 467-506, 1991). Genetic techniques have led to the identification of the genes encoding the 12- and 15-desaturases from *Arabidopsis thaliana* and other higher plant species (Okuley *et al.*, *Plant Cell* 6:147-158, 1994; Arondel *et al.*, *Science* 258:1353-1355, 1992). Recently, a *fat-1* gene encoding an n-3 fatty acid desaturase was cloned from *Caenorhabditis elegans* (Spychalla *et al.*, *Proc. Natl. Acad. Sci. USA* 94:1142-1147, 1997; see also US Patent No. 6,194,167).

SUMMARY

The present invention is based, in part, on the discovery that the *C. elegans* n-3 desaturase gene, *fat-1*, can be successfully introduced into other types of animal cells (*e.g.*, mammalian cells), where it quickly and effectively elevates the cellular n-3 PUFA content and dramatically balances the ratio of n-6:n-3 PUFAs. We have also discovered modified *C. elegans fat-1* nucleic acid sequences (*e.g.*, “optimized” sequences in which one or more of the naturally occurring codons that encode the amino acid sequence are altered (*e.g.*, GTT, which encodes the amino acid residue valine, is replaced with CTG, which also encodes valine; CGT, which encodes the amino acid residue arginine, is replaced with CGC, which also encodes arginine; and so forth)). Accordingly, *fat-1* nucleic acid sequences modified from the original by optimization of codon usage for mammalian cells are within the scope of the present invention. These sequences can be incorporated in any of the vectors and cells described below, and used in any of the methods in which the wild-type *fat-1* gene can be used. In some instances (*e.g.*, in the production of transgenic animals), the use of a codon-optimized sequence may be preferable.

More specifically, heterologous expression of the *fat-1* gene in rat cardiac myocytes rendered those cells capable of converting various n-6 PUFAs to the corresponding n-3 PUFA and changed the n-6:n-3 ratio from about 15:1 (an undesirable ratio) to 1:1 (a desirable ratio). In addition, an eicosanoid derived from n-6 PUFA (*i.e.* arachidonic acid) was significantly reduced in the transgenic cells (as described further below, levels of arachidonic acid can be assessed to determine whether a given nucleic acid encodes a biologically active desaturase; similarly, one can assess the levels of n-6 PUFA; the levels of n-3 PUFA; and the ratio of n-6:n-3 PUFAs). Accordingly, the present invention features compositions (*e.g.*, nucleic acids encoding *fat-1*, optionally and operably linked to a constitutively active or tissue-specific promoter) and methods that can be used to effectively modify the content of PUFAs in animal cells (*i.e.*, cells other than those of *C. elegans*, for example, mammalian cells such as myocytes, neurons (whether of the peripheral or central nervous system), adipocytes, endothelial cells, and cancer cells). More generally, a *fat-1* sequence or a biologically active variant thereof can be operably linked to a regulatory sequence. Regulatory sequences encompass not only promoters, but also enhancers or other expression control sequence, such as a polyadenylation signal, that facilitates expression of the nucleic acid. The modified cells (whether *in vivo* or *ex vivo* (*e.g.*, in tissue culture)), transgenic animals containing them, and food products obtained from those animals (*e.g.*, meat or other edible parts of the animals (*e.g.*, liver, kidney, or sweetbreads)) are also within the scope of the present invention.

In one embodiment, the invention features mammalian cells that contain a nucleic acid sequence encoding the *C. elegans* n-3 desaturase or biologically active variants (*e.g.*, fragments or other mutants) thereof, including variants that encode the *C. elegans* fat-1 protein (*e.g.*, the variant shown in Fig. 18). Biologically active variants of the n-3 desaturase enzyme are variants that retain enough of the biological activity of a wild-type n-3 desaturase to be therapeutically or clinically effective (*i.e.*, variants that are useful in treating patients, producing transgenic animals, or conducting diagnostic or other laboratory tests). For example, variants of n-3 desaturase can be mutants or fragments of that enzyme that retain at least 25% of the biological activity of wild-type n-3 desaturase. For example, a fragment of an n-3 desaturase enzyme is a biologically active variant of the full-length enzyme when the fragment converts n-6 fatty acids to n-3 fatty acids at

least 25% as efficiency as the wild-type enzyme does so under the same conditions (*e.g.*, 30, 40, 50, 75, 80, 90, 95, or 99% as efficient as wild-type n-3 desaturase). Variants may also contain one or more amino acid substitutions (*e.g.*, 1%, 5%, 10%, 20%, 25% or more of the amino acid residues in the wild-type enzyme sequence can be replaced with another amino acid residue). These substitutions can constitute conservative amino acid substitutions, which are well known in the art. Cells that express a *fat-1* sequence (optionally, operably linked to a constitutively active or tissue-specific promoter) are valuable aids to research because they provide a convenient system for characterizing the functional properties of the *fat-1* gene and its product (cells in tissue culture are particularly convenient, but the invention is not so limited). They also allow one to study any cellular mechanism mediated by n-3 fatty acids without the lengthy feeding procedures of cells or animals that are currently required, and they serve as model systems that can be used, for example, to evaluate existing methods and to design new methods for effectively transferring sequences encoding an n-3 desaturase into cells *in vivo*. In any of these contexts (*e.g.*, whether the compositions of the invention are being used to treat patients, to generate transgenic animals, or in cell culture assays), nucleic acids encoding *fat-1* or a biologically active variant thereof can be co-expressed (by way of the same or a separate vector) with a heterologous gene. The heterologous gene can be, for example, another therapeutic gene (*e.g.*, a receptor for a small molecule or chemotherapeutic agent) or a marker gene (*e.g.*, a sequence encoding a fluorescent protein, such as green fluorescent protein (GFP) or enhanced (EGFP)). Variant *fat-1* nucleic acids, including optimized *fat-1* nucleic acids, may also encode proteins that exhibit certain advantages over their wild-type counterparts. For example, the variant sequence may be more efficacious in expressing the desaturase (in cells in culture or *in vivo*).

Any of the nucleic acid molecules of the invention may be “isolated” (*i.e.*, in an environment different from the environment in which they naturally occur). For example, the nucleic acids may be incorporated into a plasmid or other vector, or linked to one or more heterologous sequences, including regulatory elements such as promoters and enhancers.

The nucleic acids of the invention can be formulated for administration to a patient. For example, they can be suspended in sterile water or a physiological buffer (*e.g.*, phosphate-buffered saline) for oral or parenteral administration to a patient (*e.g.*, intravenous, intramuscular, intradermal, or subcutaneous injection (in the event the patient has a tumor, the compositions can be injected into the tumor or administered to the tissue surrounding the site from which a tumor was removed) or by inhalation).

The invention also features transgenic animals (including any animal kept as livestock or as a food source) that express the *C. elegans* n-3 desaturase gene or a biologically active variant thereof. Given the discovery that a *C. elegans fat-1* gene can be efficiently expressed when delivered to a mammalian cell, this gene can be used to generate transgenic mice or larger transgenic animals (such as cows, pigs, sheep, goats, rabbits or any other livestock or domesticated animal) according to methods well known in the art. Depending on whether the construct used contains a constitutively active promoter or a tissue-specific promoter (*e.g.*, a promoter that is active in skeletal muscle, breast tissue, the colon, neurons, retinal cells, pancreatic cells (*e.g.*, islet cells) *etc.*) the *fat-1* gene can be expressed globally or in a tissue-specific manner. The cells of the transgenic animals will contain an altered PUFA content that, as described further below, is more desirable for consumption. Thus, transgenic livestock (or any animal that is sacrificed for food) that express the desaturase enzyme encoded by the *fat-1* gene will be superior (*i.e.*, healthier) sources of food. Food obtained from these animals can be provided to healthy individuals or to those suffering from one or more of the conditions described below.

As noted, the invention features methods of treating patients (including humans and other mammals) who have a condition associated with an insufficiency of n-3 PUFA or an imbalance in the ratio of n-3:n-6 PUFAs by administering a nucleic acid encoding an n-3 desaturase or a biologically active variant thereof (*e.g.*, a fragment or other mutant). Alternatively, one can administer the protein encoded. The methods can be carried out with patients who have an arrhythmia or cardiovascular disease (as evidenced, for example, by high plasma triglyceride levels or hypertension), cancer (*e.g.*, breast cancer or colon cancer), inflammatory or autoimmune diseases (such as rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease (IBD), asthma, chronic

obstructive pulmonary disease, lupus, diabetes, Sjogren's syndrome transplantation, ankylosing spondylitis, polyarteritis nodosa, reiter's syndrome, and scleroderma), a malformation (or threatened malformation, as occurs in premature infants) of the retina and brain, diabetes, obesity, skin disorders, renal disease, ulcerative colitis, Crohn's disease, chronic obstructive pulmonary disease, or who are at risk of rejecting a transplanted organ. Given that *fat-1* expression can also inhibit cell death (by apoptosis) in neurons, the methods of the invention can also be used to treat or prevent (*e.g.*, inhibit the likelihood of, or the severity of) neurodegenerative diseases. Accordingly, the invention features methods of treating a patient who has (or who may develop) a neurodegenerative disease such as Parkinson's disease, Alzheimer's disease, Huntington's disease (HD), spinal and bulbar muscular atrophy (SBMA; also known as Kennedy's disease), dentatorubral-pallidoluysian atrophy, spinocerebellar ataxia type 1 (SCA1), SCA2, SCA6, SCA7, or Machado-Joseph disease (MJD/SCA3) (Reddy *et al. Trends Neurosc.* 22:248-255, 1999). As a balanced n-6:n-3 ratio is essential for normal growth and development, and as noted above, the methods of the invention can be advantageously applied to patients who have no discernable disease or condition.

Abbreviations used herein include the following: AA for arachidonic acid (20:4n-6); DHA for docosahexaenoic acid (22:6n-3); EPA for eicosapentaenoic acid (20:5n-3); GFP for green fluorescent protein; Ad.GFP for adenovirus carrying GFP gene; Ad.GFP.fat-1 for adenovirus carrying both fat-1 gene and GFP gene; and PUFAs for polyunsaturated fatty acids.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, useful methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflicting subject matter, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description, the drawings, and the Examples.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a collection of four photomicrographs showing gene transfer efficiency. Rat cardiac myocytes were infected with Ad.GFP (left panels; control) or Ad.GFP.fat-1 (right panels). Forty-eight hours after infection, cardiomyocytes were visualized with bright light (upper panels) and at 510 nm of blue light (lower panels). Coexpression of GFP demonstrates visually that the transgene is being expressed in cells with a high efficiency.

Fig. 2 is an autoradiogram of a ribonuclease (RNase) protection assay of fat-1 transcript levels in cardiac myocytes infected with Ad.GFP (control) and myocytes infected with Ad.GFP.fat-1. Total RNA (10 μ g) isolated from the cardiomyocytes was hybridized with anti-sense RNA probes, digested with RNase and resolved by electrophoresis through a denaturing polyacrylamide gel. The fat-1 mRNA was visualized by autoradiography. A probe targeting β -actin gene was used as control.

Fig. 3. is a pair of partial gas chromatograph traces showing fatty acid profiles of total cellular lipids extracted from control cardiomyocytes infected with Ad.GFP and cardiomyocytes infected with Ad.GFP.fat-1.

Fig. 4 is a bar graph depicting prostaglandin E₂ levels in control cardiomyocytes and cardiomyocytes expressing the fat-1 gene (as determined by enzyme immunoassay). Values are means \pm SDs of three experiments and are expressed as % of control. * p <0.01.

Fig. 5 is a Table showing the polyunsaturated fatty acid composition of total cellular lipids from control cardiomyocytes and the transgenic cardiomyocytes expressing a *C. elegans* fat-1 cDNA.

Fig. 6 is a flowchart of an experimental protocol.

Fig. 7 is a flowchart of an experimental protocol.

Fig. 8 is a flowchart of an experimental protocol.

Fig. 9 is a pair of partial gas chromatograph traces showing fatty acid profiles of total cellular lipids extracted from control neurons and neurons infected with Ad-GFP-*fat-1*. Fig. 10 is a Table comparing the PUFA composition of total cellular lipids from

rat cortical neurons (control) and transgenic cells expressing a *C. elegans fat-1* cDNA (*fat-1*).

Fig. 11 is a bar graph showing the results of an enzyme immunoassay of prostaglandin E₂ levels in control neurons and neurons expressing the *fat-1* gene. Ad-GFP-*fat-1* infected neurons have lower levels of PGE₂ relative to control. Values are means \pm SD of three experiments and expressed as a percentage of control. *P < 0.01.

Fig. 12 is a bar graph representing the results of an MTT assay of cell viability in control and *fat-1* expressing cultures. After 24 hours of growth factor withdrawal, the cell viability of neurons expressing the *fat-1* gene is 50% higher than control cells (p < 0.01).

Fig. 13 is a pair of tracings showing differential responses of myocytes infected with Ad.GFP and myocytes infected with Ad.GFP.*fat-1* to 7.5mM extracellular calcium.

Fig. 14 is a line graph showing tumor volume over time (0-4 weeks after viral injection) and thus, the effect of gene transfer on tumor growth. Breast cancer cells (MDA-MB-231) were implanted subcutaneously on the back of nude mice. Three weeks later, the mice were treated with Ad.GFP-*fat-1* or Ad.GFP (control; 50 μ l, 10¹² VP/m) by intratumoral injection.

Fig. 15 is a table showing PUFA compositions of total cellular lipids from control MCF-7 cells and the transgenic MCF-7 cells expressing a *C. elegans fat-1* cDNA.

Fig. 16 is a bar graph depicting the results of an enzyme immunoassay of prostaglandin E₂ levels in control MCF-7 cells and MCF-7 cells expressing *fat-1* gene. Values are means \pm SE of three experiments and expressed as a percentage of control. (*P < 0.05).

Figs. 17A and 17B are representations of the nucleotide sequence of the *C. elegans fat-1* cDNA and the deduced amino acid sequence of the Fat-1 polypeptide.

Fig. 18 is a representation of an optimized *fat-1* nucleic acid sequence.

Fig. 19 is a pair of partial gas chromatograph traces showing the differential polyunsaturated fatty acid profiles of total lipids extracted from skeletal muscles of a wild-type mouse (WT, upper panel) and a *fat-1* transgenic mouse (TG, lower panel). Both the wild-type mouse and the transgenic mouse were 8 week-old female mice, and they were fed the same diet. The levels of n-6 polyunsaturated acids (18:2n-6, 20:4n-6, 22:4n-6 and 22:5n-6) are low, whereas n-3 fatty acids (marked with *) are abundant in the

transgenic muscle (lower panel) compared with the wild type muscle (upper panel). In the wild type animals, the polyunsaturated fatty acids found in the tissues are mainly (98%) the n-6 linoleic acid (LA, 18:n-6) and arachidonic acid (AA, 20:4n-6) with trace (or undetectable) amount of n-3 fatty acids. In contrast, there are large amounts of n-3 polyunsaturated fatty acids, including linolenic acid (ALA, 18:3n-3), eicosapentaenoic acid (EPA, 20:5n-3), docosapentaenoic acid (DPA, 22:5n-3) and docosahexaenoic acid (DHA, 22:6n-3), in the tissues of transgenic mice. Accordingly, the levels of the n-6 fatty acids LA and AA in the transgenic tissues are significantly reduced, indicating a conversion of n-6 to n-3 fatty acids. The resulting ratio of n-6 to n-3 fatty acids in the tissues of transgenic animals was close to 1. This n-3 rich profile of lipid with a balanced ratio of n-6 to n-3 and a more balanced AA/(EPA+DPA+DHA) can be observed in all of the organs/tissues tested, as listed in Table 1.

DETAILED DESCRIPTION

The studies described below demonstrate that, *inter alia*, a nucleic acid molecule encoding an n-3 desaturase can be efficiently expressed in a variety of mammalian cell types and, as a consequence, those cells produce significant amounts of n-3 PUFA from endogenous n-6 PUFA and have a more balanced ratio of n-6 to n-3 PUFA (1:1). The studies were carried out using recombinant adenoviral expression vectors, which can mediate gene transfer *in vivo* or *in vitro*. Adenoviral vectors expressing *fat-1*, or biologically active variants thereof, as well as other types of viral and non-viral expression vectors are within the scope of the invention now claimed. Other viral vectors that can be employed as expression constructs in the present invention include vectors derived from viruses such as vaccinia virus (*e.g.*, a pox virus or a modified vaccinia virus ankara (MVA)), an adeno-associated virus (AAV), or a herpes viruses. These viruses offer several attractive features for various mammalian cells. For example, herpes simplex viruses (*e.g.*, HSV-1) can be selected to deliver *fat-1* or a biologically active variant thereof, to neuronal cells (and thereby treat patients with neurodegenerative conditions).

Other retroviruses, liposomes, and plasmid vectors are also well known in the art and can also be used (*e.g.*, the expression vector pUR278 can be used when one wishes to

fuse a *fat-1* sequence to the *lacZ* gene; *lacZ* encodes the detectable marker β -galactosidase (*see, e.g.,* Ruther *et al.*, *EMBO J.*, 2:1791, 1983). A *fat-1* sequence can also be fused to other types of heterologous sequences, such as a sequence that encodes another therapeutic gene or a sequence that, when expressed, improves the quantity or quality (*e.g.,* solubility or circulating half-life) of the fusion protein. For example, pGEX vectors can be used to express the proteins of the invention fused to glutathione S-transferase (GST). In general, such fusion proteins are soluble and can be easily purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors (Pharmacia Biotech Inc; Smith and Johnson, *Gene* 67:31-40, 1988) are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety. Other fusion partners include albumin and a region (*e.g.,* the Fc region) of an immunoglobulin molecule (*e.g.,* IgG, IgA, IgM, or IgE). Other useful vectors include pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ), which fuse maltose E binding protein and protein A, respectively, to an n-3 desaturase.

Transgene expression can be sufficiently prolonged from episomal systems, so that readministration of the vector, with its transgene, is not necessary. Alternatively, the vector can be designed to promote integration into the host genome, preferably in a site-specific location, which would help ensure that the transgene is not lost during the cell's lifetime. Whatever the means of delivery, transcriptional control, exerted by the host cell, would promote tissue specificity and regulate transgene expression.

The expression vector will be selected or designed depending on, for example, the type of host cell to be transformed and the level of protein expression desired. For example, when the host cells are mammalian cells, the expression vector can include viral regulatory elements, such as promoters derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. The nucleic acid inserted (*i.e.,* the sequence to be expressed; here, *fat-1*) can also be modified to encode residues that are preferentially utilized in *E. coli* (Wada *et al.*, *Nucleic Acids Res.* 20:2111-2118, 1992). These modifications can be achieved by standard recombinant techniques. More generally, the expression vectors of the invention can be designed to express proteins in prokaryotic or eukaryotic cells. For example, polypeptides of the invention can be expressed in

bacterial cells (*e.g.*, *E. coli*), fungi, yeast, or insect cells (*e.g.*, using baculovirus expression vectors). For example, a baculovirus such as Autographa californica nuclear polyhedrosis virus (AcNPV), which grows in *Spodoptera frugiperda* cells, can be used as a vector to express foreign genes.

As noted elsewhere, the expression vectors and nucleic acids used to express *fat-1* can also contain a tissue-specific promoter. Such promoters are known in the art and include, but are not limited to liver-specific promoters (*e.g.*, albumin; Miyatake *et al.*, 1997), muscle-specific promoters (*e.g.*, myosin light chain 1 (Shi *et al.*, 1997) α -actin), pancreatic-specific promoter (*e.g.*, insulin or glucagon promoters), neural-specific promoters (*e.g.*, the tyrosine hydroxylase promoter or the neuron-specific enolase promoter), endothelial cell-specific promoters (*e.g.*, von Willebrandt; Ozaki *et al.*, 1996), and smooth muscle-cells specific promoters (*e.g.*, 22a; Kim *et al.*, 1997). Tumor-specific promoters are also being used in developing cancer therapies, including tyrosine kinase-specific promoters for B16 melanoma (Diaz *et al.*, 1998), DF3/MUC1 for certain breast cancers (Wen *et al.*, 1993; for breast cancer, an adipose-specific promoter region of human aromatase cytochrome p450 (p450arom) can also be used (*see* U.S. Patent No. 5,446,143; Mahendroo *et al.*, *J. Biol. Chem.* 268:19463-19470, 1993; and Simpson *et al.*, *Clin. Chem.* 39:317-324, 1993). An α -fetoprotein promoter can be used to direct expression in hepatomas (Chen *et al.*, 1995). The vectors and other nucleic acid molecules of the invention (*e.g.*, the *fat-1* cDNA *per se*) can also include sequences that limit the temporal expression of the transgene. For example, the transgene can be controlled by drug inducible promoters by, for example including cAMP response element enhancers in a promoter and treating the transfected or infected cell with a cAMP modulating drug (Suzuki *et al.*, 1996). Alternatively, repressor elements can prevent transcription in the presence of the drug (Hu *et al.*, 1997). Spatial control of expression has also been achieved by using ionising radiation (radiotherapy) in conjunction with the *erg1* gene promoter (Hallaham *et al.*, 1995). Constructs that contain such regulatory sequences are within the scope of the present invention.

In the examples that follow, RNA analysis and enzymatic assays were performed to assess gene expression, and gas chromatography-mass spectrometry were used to determine fatty acid profiles (these are standard techniques that one of ordinary skill in

the art could use to assess any variant of the *fat-1* sequence for biological activity; or incorporate in any method of assessing a sample obtained from a patient for *fat-1* expression).

Some of the studies described below were conducted using cortical neurons. *Fat-1* expression not only modified the cellular n-6:n-3 fatty acid ratio and eicosanoid profile in these neurons, but also protected the cells from apoptosis, thereby increasing cellular viability. More specifically, *fat-1* expression modified the fatty acid ratio and protected rat cortical neurons against growth factor withdrawal-induced apoptosis in the absence of supplementation with exogenous n-3 PUFAs. Accordingly, the nucleic acid molecules (and other compositions) described herein can be used as neuroprotectants, which can be administered to premature infants and to older patients having any neurodegenerative disease (alternatively, the molecules or other compositions can be delivered to an animal, parts of which are then consumed by the patient). The protective effect of gene transfer on neuronal apoptosis mimics the protective effects of n-3 fatty acid supplementation.

The positive results obtained with neurons are especially encouraging because n-3 PUFA deficiency leads to abnormal development of the retina and the brain, particularly in premature infants (Uauy *et al.*, *Lipids* 36:885-895, 2001), and animals deficient in n-3 PUFA show deficits in memory, spatial and context-dependent learning, and loss of visual acuity (Carrie *et al.*, *Neurosci. Lett.* 266:69-72, 1999; Yehuda *et al.*, *J. Neurosci. Res.* 56:565-70, 1999). There are also indications that various neurological disease states in humans are associated with an n-3 deficient status (Vancassel *et al.*, *Prost. Leuk. Ess. Fatt. Acids* 65:1-7, 2001; Hoffman and Birch, *World Rev. Nutr. Diet* 83:52-69, 1998).

The biological functions of PUFAs are described further here, as these functions bear on the types of conditions amenable to treatment with the nucleic acid molecules (and other compositions) described herein. PUFAs are important structural components of membrane phospholipids and are precursors of families of signaling molecules (eicosanoids) including prostaglandins, thromboxanes, and leukotrienes (Needleman *et al.*, *Ann. Rev. Biochem.* 55:69-102, 1986; Smith and Borgeat, *In Biochemistry of Lipids and Membranes*, D.E. Vance & J.E. Vance, Eds., Benjamin/Cummings, Menlo Park, CA, 00 325-360, 1986). The eicosanoids derived from PUFAs play a key role in modulating

inflammation, cytokine release, the immune response, platelet aggregation, vascular reactivity, thrombosis and allergic phenomena (Dyerberg *et al.*, *Lancet* 2:117-119, 1978; Cyerberg and Bang, *Lancet* 2:433-435, 1979; James *et al.*, *Am. J. Clin Nutr.* 7:343S-3438S, 2000; Calder, *Ann. Nutr. Metab.* 41:203-234, 1997). The principal fatty acid precursors of these signaling compounds are arachidonic acid (AA, 20:4n6), providing an n-6 substrate that is responsible for the major synthesis of the series 2 compounds, and eicosapentaenoic acid (EPA, 20:5n3), an n-3 substrate that is responsible for the parallel synthesis of many series 3 eicosanoids with an additional double bond. The n-6:n-3 ratio in phospholipids modulates the balance between eicosanoids of the 2 and 3 series derived from AA and EPA. The eicosanoids derived from AA (series 2) and EPA (series 3) are functionally distinct and some have important opposing physiological functions (Dyerberg *et al.*, *Lancet* 2:117-119, 1978; Cyerberg and Bang, *Lancet* 2:433-435, 1979; James *et al.*, *Am. J. Clin Nutr.* 7:343S-3438S, 2000; Calder, *Ann. Nutr. Metab.* 41:203-234, 1997). Series 3 eicosanoids are weak agonists or, in some cases, antagonists of series 2 eicosanoids. For example, eicosanoids of the 2 series promote inflammation and platelet aggregation, and activate the immune response, whereas series 3 eicosanoids tend to ameliorate these effects. In addition, PUFAs, in the form of free fatty acids, are involved in gene expression and intercellular cell-to-cell communication (Price *et al.*, *Curr. Opin. Lipidol* 11:3-7, 2000; Sellmayer *et al. Lipids* 31 Suppl:S37-S40, 1996; vonSchacky, *J. Lab. Clin. Med.* 128:5-6, 1996). Thus, PUFA can exhibit many diverse biological effects.

The compositions and methods described herein can be used to treat a variety of specific conditions as well as to improve general health. Any condition that is amenable to treatment by administration of n-3 PUFAs is amenable to treatment by way of the methods of the present invention, which comprise administration of a gene encoding an n-3 desaturase (*e.g.*, the *C. elegans fat-1* gene). Some of the conditions amenable to treatment are described below.

n-3 PUFAs have attracted considerable interest as pharmaceutical and nutraceutical compounds (Connor, *Am. J. Clin. Nutr.* 70:560S-569S, 1999; Simopoulos, *Am. J. Clin. Nutr.* 70:562S-569S, 1999; Salem *et al.*, *Lipids* 31:S1-S326, 1996). During the past 25 years, more than 4,500 studies have explored the effects of n-3 fatty acids on

human metabolism and health (e.g., cardiovascular health). From epidemiology to cell culture and animal studies to randomized controlled trials, the cardioprotective effects of omega-3 fatty acids have been recognized (Leaf and Kang, *World Rev. Nutr. Diet.* 83:24-37, 1998; De Caterina *et al.*, Eds., *n-3 Fatty Acids and Vascular Disease*, Springer-Verlag, London, 1999, pp 166; O'Keefe and Harris, *Mayo Clin. Proc.* 75:607-614, 2000). The predominant beneficial effects include a reduction in sudden death (Albert *et al.*, *JAMA* 279:23-28, 1998; Siscovick *et al.*, *JAMA* 274:1363-1367, 1995), decreased risk of arrhythmia (Kang and Leaf, *Circulation* 94:1774-1780, 1996), lower plasma triglyceride levels (Harris, *Am. J. Clin. Nutr.* 65:1645S-1654S, 1997), and a reduced blood-clotting tendency (Agren *et al.*, *Prostagland. Leukot. Essent. Fatty Acids* 57:419-421, 1997; Mori *et al.*, *Arterioscler. Throm. Basc. Biol.* 17:279-286, 1997). Evidence from epidemiological studies shows that another n-3 fatty acid, α -linolenic acid, reduces risk of myocardial infarction (Guallar *et al.*, *Arterioscler. Thromb. Vasc. Biol.* 19:1111-1118, 1999) and fatal ischemic heart disease in women (Hu *et al.*, *Am. J. Clin. Nutr.* 69:890-897, 1999). Several randomized controlled trials recently have demonstrated beneficial effects of both α -linolenic acid (de Lorgeril *et al.*, *Circulation* 99:779-785, 1999) and marine ω -3 fatty acids (Singh *et al.*, *Cardiovasc. drugs ther.* 11:485-491, 1997; Von Schacky *et al.*, *Ann. Intern. Med.* 130:554-562, 1999; GISSI-Prevenzione Investigators, *Lancet* 354:447-455, 1999) on both coronary morbidity and mortality in patients with coronary disease. The n-3 fatty acid, EPA, exerts anticancer activity *in vitro* and in animal models of experimental cancer (Bougnoux, *Curr. Opin. Clin. Nutr. Metab. Care* 2:121-126, 1999; Cave, *Breast Cancer Res. Treat.* 46:239-246, 1997). Human studies show that populations whose diets are rich in EPA exhibit a remarkably low incidence of cancer (Rose and Connolly, *Pharmacol. Ther.* 83:217-244, 1999). Supplementation with n-3 PUFAs shows therapeutic effects on inflammatory and autoimmune diseases such as arthritis (Kremer, *Am. J. Clin. Nutr.* 71:349S-351S, 2000; Ariza-Ariza *et al.*, *Semin. Arthritis Rheum.* 27:366-370, 1998; James *et al.*, *Am. J. Clin. Nutr.* 71:343S-348S), and studies with nonhuman primates (Neuringer *et al.*, *Proc. Natl. Acad. Sci. USA* 83:4021-4025, 1986) and human newborns (Uauy *et al.*, *Proc. Nutr. Soc.* 59:3-15, 2000; Uauy *et al.*, *Lipids* 31:S167-176, 1996) indicate that the n-3 fatty acid, DHA, is essential for the normal functional development of the retina and brain,

particularly in premature infants. Furthermore, n-3 PUFA have been shown to have beneficial effects on many other clinical problems, such as hypertension (Appel *et al.*, *Arch. Intern. Med.* 153:1429-1438, 1993), diabetes (Raheja *et al.*, *Ann. N.Y. Acad. Sci.* 683:258-271, 1993), obesity (Clarke, *Br. J. Nutr.* 83:S59-66, 2000), skin disorders (Ziboh, *World Rev. Nutr. Diet.* 66:425-435, 1991), renal disease (De Caterina *et al.*, *Kidney Int.* 44:843-850, 1993), ulcerative colitis (Stenson *et al.*, *Ann. Intern. Med.* 116:609-614, 1992), Crohn's disease (Belluzzi *et al.*, *N. Engl. J. Med.* 334:1557-1560, 1996), chronic obstructive pulmonary disease (Shahar *et al.*, *N. Engl. J. Med.* 331:228-233, 1994), and transplanted organ rejection (Otto *et al.*, *Transplantation* 50:193-198, 1990). In general, a balanced n-6:n-3 ratio of the body lipids is essential for normal growth and development and plays an important role in the prevention and treatment of many clinical problems. The diseases, disorders, and conditions described above are amenable to treatment with the nucleic acid molecules (and other compositions) described herein.

According to recent studies (Simopoulos, *Poultry Science* 79:961-970, 2000), the ratio of n-6 to n-3 essential fatty acids in today's diet is around 10-20:1. This indicates that present Western diets are deficient in n-3 fatty acids compared with the diet on which humans evolved and their genetic patterns were established ($n-6/n-3 = 1:1$) (Leaf and Weber, *Am. J. Clin Nutr.* 45:1048-1053, 1987). Since the n-6 and n-3 fatty acids are metabolically and functionally distinct and have important opposing physiological functions, their balance is important for homeostasis and normal development. However, n-3 and n-6 PUFAs are not interconvertible in the human body because mammalian cells lack the enzyme n-3 desaturase. Therefore, the balance between n-6 and n-3 PUFA in biological membranes is regulated based on dietary supply. Elevating the tissue concentrations of n-3 fatty acids in human subjects or animals relies on increased consumption of n-3 PUFA-enriched foods or n-3 PUFA supplements. Given the potential therapeutic actions of n-3 PUFAs, an international scientific working group has recommended diets in which the intake of n-6 fatty acids is decreased and the intake of n-3 fatty acids is increased (Simopoulos, *Food Australia* 51:332-333, 1999). The American Heart Association has also recently made such a dietary recommendation (AHA Dietary Guidelines: Revision 2000, *Circulation* 102:2284-2299, 2000).

Although dietary supplementation with n-3 PUFA is a safe intervention, it has a number of limitations. For example, to achieve a significant increase in tissue concentrations of n-3 PUFA *in vivo* requires a chronic intake of high doses of n-3 PUFA for a period of at least 2-3 months. Bioavailability of fatty acids to cells from the diet involves a series of physiological processes including digestion, absorption, transport and metabolism of fat. Thus, the efficacy of dietary intervention depends on the physiological and health status of an individual. A patient in critical condition or who has a gastrointestinal disorder is unlikely to be able to ingest or absorb fatty foods or n-3 PUFA supplements. In addition, encapsulated fish oil supplements are unlikely to be suited to daily use over a person's lifetime because of their high caloric content. Moreover, ingestion of some species of fish from costal waters and lakes may carry toxic amounts of mercury or organic toxins, and effective dietary intervention requires a disciplined change in dietary habits that some people may not be able to sustain. In view of the foregoing, there is a great need for the means to quickly and effectively increase cellular n-3 PUFA content and balance the n-6:n-3 ratio without resorting to long-term intake of fish or fish oil supplements. This need is met by the methods of the present invention, which create an alternative food source (via transgenic livestock whose cells contain substantially more n-3 PUFAs than in non-transgenic animals) or which provide for administration of a gene encoding an n-3 desaturase enzyme to patients (*e.g.*, human patients). A particular advantage of the present methods is that they not only elevate tissue concentrations of n-3 PUFAs, but also simultaneously decreases the levels of excessive endogenous n-6 PUFA.

EXAMPLES

Example 1: Construction of a recombinant adenovirus.

A recombinant adenovirus carrying the *fat-1* gene was constructed following procedures similar to those described by He *et al.* (*Proc. Natl. Acad. Sci. USA* 95:2509-2514, 1998). The n-3 fatty acid desaturase cDNA (*fat-1* gene) in pCE8 was kindly provided by Dr. J. Browse (Washington State University) (but can be synthesized or cloned using information and techniques available to those of ordinary skill in the art; *see* Spsychalla *et al.*, *Proc. Natl. Acad. Sci. USA* 94:1142-1147, 1997; US Patent

No. 6,194,167; and Fig. 17A and 17B). The cDNA insert of pCE8 was excised from the plasmid with an *EcoRI/KpnI* double digest, inserted into a shutter vector, and then recombined with an adenoviral backbone according to the methods of He *et al.* (*supra*). Two, first-generation type 5 recombinant adenoviruses were generated: Ad.GFP, which carries the green fluorescent protein (GFP, as reporter gene) under control of the cytomegalovirus (CMV) promoter, and Ad.GFP.fat-1, which carries both the *fat-1* and GFP genes, each under the control of separate CMV promoters. The recombinant viruses were prepared as high titer stocks through propagation in 293 cells, as described previously (Hajjar *et al.* *Circulation* 95:423-429, 1997). The constructs were confirmed by enzymatic digestion and by DNA sequence analysis. *See also* Hajjar *et al.*, *Circulation* 95:423-429, 1997 and Hajjar *et al.*, *Circ. Res.* 81:145-153, 1997.

Wild-type adenovirus contamination can be assessed and shown to be excluded by the absence of both PCR-detectable E1 sequences and cytopathic effects on the nonpermissive A549 cell line. Alternative adenoviral vectors with other promoters or adeno-associated viral (AAV) vectors can be constructed if necessary or desired.

Example 2: Culture and infection of cardiac myocytes with adenovirus.

Cardiac myocytes were isolated from one-day-old rats using the National Cardiomyocyte Isolation System (Worthington Biochemical Corp., Freehold, NJ). The isolated cells were placed in 6-well plates and cultured in F-10 medium containing 5% fetal bovine serum and 10% horse serum at 37°C in a tissue culture incubator with 5% CO₂ and 98% relative humidity. Cells were used for experiments after 2-3 days of culture. Viral infection was carried out by adding viral particles at different concentrations (5×10^9 - 10^{10} pfu) to culture medium containing 2% fetal bovine serum (FBS). After a 24 hour incubation, the infection medium was replaced with normal (15% serum), culture medium supplemented with 10 µM of 18:2n-6 and 20:4n-6. About 48 hours after infection, the cells can be used (*e.g.*, one can then analyze gene expression, fatty acid composition, viability, or growth (*e.g.*, proliferation or rate of division)).

Example 3: Detecting *fat-1* expression with fluorescence microscopy and RNA analysis.

Gene expression can be assessed by many methods known in the art of molecular biology. Here, expression of *fat-1* in cardiac myocytes, infected as described above, was assessed by visual examination of infected cells and a ribonuclease (RNase) protection assay.

More specifically, the coexpression of GFP allowed us to identify the cells that were infected and expressed the transgene. About 48 hours after infection, almost all of the cells (>90%) exhibited bright fluorescence, indicating a high efficiency of gene transfer and a high expression level of the transgene (see Fig. 1). Expression of *fat-1* transcripts was also determined by RNase protection assay using a RPA III™ kit (Ambion). Briefly, total RNA was extracted from cultured cells using an RNA isolation kit (Qiagen) according to the manufacturer's protocol. The plasmid containing the *fat-1* gene, pCE8, was linearized and used as a transcription template. Anti-sense RNA probes were transcribed *in vitro* using ³³P-UTP, hybridized with the total RNA extracted from the myocytes, and digested with RNase to remove non-hybridized RNA and probe. The protected RNA:RNA was resolved by electrophoresis through a denaturing gel and subjected to autoradiography. A probe targeting the β -actin gene was used as a control. *Fat-1* mRNA was not detected in cells infected with AD.GFP (also used as a control), but was abundant in cells infected with Ad.GFP.fat-1 (Fig. 2). This result indicates that adenovirus-mediated gene transfer confers very high expression of *fat-1* gene in rat cardiac myocytes that normally lack the gene.

Example 4: Lipid analysis; the effect of n-3 desaturase on fatty acid composition

By lipid analysis, one can determine whether the expression of a *fat-1* gene in cardiac myocytes (or any other cell type) converts n-6 fatty acids to n-3 fatty acids and, thereby, changes the fatty acid composition of the cell. Following infection with the adenoviruses described above, cells were incubated in medium supplemented with n-6 fatty acids (10 μ M 18:2n-6 and 10 μ M 20:4n-6) for 2-3 days. After the incubation, the fatty acid composition of total cellular lipids was analyzed as described previously (Kang *et al.*, *Biochim. Biophys. Acta.* 1128:267-274, 1992; Weylandt *et al.*, *Lipids* 31:977-982, 1996).

Lipid was extracted with chloroform/methanol (2:1, v/v) containing 0.005% butylated hydroxytoluene (as antioxidant). Fatty acid methyl esters were prepared using 14% BF₃/methanol reagent. Fatty acid methyl esters are quantified by GC/MS using a HP5890 Series II gas chromatograph equipped with a Supelcowax SP-10 capillary column attached to a HP-5971 mass spectrometer. The injector and detector are maintained at 260°C and 280°C, respectively. The oven program is initially maintained at 150°C for 2 minutes, then ramped to 200°C at 10°C/min and held for 4 minutes, ramped again at 5°C/min to 240°C, held for 3 minutes, and finally ramped to 270°C at 10°C/min and maintained for 5 minutes. Carrier gas flow rate is maintained at a constant 0.8 mL/min throughout. Total ion monitoring is performed, encompassing mass ranges from 50-550 amu. Fatty acid mass is determined by comparing areas of various analyzed fatty acids to that of a fixed concentration of internal standard.

The fatty acid profiles were remarkably different between the control cells infected with Ad.GFP and the cells infected with Ad.GFP.fat-1 (Fig. 3). Moreover, cells infected with Ad.GFP showed no change in their fatty acid profiles when compared with non-infected cells. In the cells expressing the *fat-1* gene (n-3 desaturase), almost all kinds of n-6 fatty acids were largely converted to the corresponding n-3 fatty acids, namely, 18:2n-6 to 18:3n-3, 20:2n-6 to 20:3n-3, 20:3n-6 to 20:4n-3, 20:4n-6 to 20:5n-3, and 22:4n-6 to 22:5n-3. As a result, the fatty acid composition of the cells expressing *fat-1* was significantly changed with respect to that of the control cells infected with Ad.GFP (Fig. 5). Importantly, the ratio of n-6:n-3 was reduced from 15:1 in the control cells to 1:1.2 in the cells expressing the n-3 fatty acid desaturase.

Example 5: Measuring eicosanoids following *fat-1* expression

Since 20:4n-6 (AA) and 20:5n-3 (EPA) are the precursors of 2-series and 3-series of eicosanoids, respectively, differences in the contents of AA and EPA may lead to a difference in production of eicosanoids in the cells. Thus, we measured the production of eicosanoids in the infected cells following stimulation with calcium ionophore A23187 by using a EIA kit that specifically detect prostaglandin E₂ with a 16% cross-reactivity with prostaglandin E₃. More specifically, Prostaglandin E₂ was measured by using enzyme immunoassay kits (Assay Designs, Inc) following the manufacturer's protocol.

(The cross-reactivity with PGE₃ is 16%). Cultured cells were washed and serum-free medium containing calcium ionophore A23187 (5 μ M). After a 10 minute incubation, the conditioned medium was recovered and subjected to eicosanoid measurement. The amount of prostaglandin E₂ produced by the control cells was significantly higher than that produced by cells expressing the n-3 desaturase encoded by *fat-1* (Fig. 4).

Example 6: Analysis of animal cells in culture

In this example and the two that follow, we set out three different experimental models: cultured cells (other types of cultured cells are tested further below), adult rats, and transgenic mice. As shown above, the cultured cell model can be used to characterize the enzymatic properties and biochemical effects of the n-3 desaturase when expressed in mammalian cells *in vitro*; the adult rat model can be used to evaluate the efficacy with which a transferred *fat-1* gene can elevate tissue concentrations of n-3 PUFA *in vivo*, and the transgenic mouse model can be used to assess the long-term and systematic effects of the transgene on lipid composition of various tissues or organs *in vivo*. For the first two models, the introduction of the *fat-1* gene into mammalian cells/tissues will be carried out by mean of adenoviral gene transfer (mediated by recombinant adenoviruses). For the last model, gene transfer will be carried out by microinjection of the transgene into fertilized mouse eggs. Following gene transfer, the expression profile of the transferred gene can be characterized by mRNA and/or protein analysis (*see, e.g.,* Example 3, above), and the biochemical effects, mainly the fatty acid composition of the cells or tissues, will be determined by GC-MS technology (*see, e.g.,* Example 4, above). Eicosanoids will be measured by enzyme immunoassay (*see, e.g.,* Example 5). Changes are identified by comparing the data obtained from *fat-1*-expressing cells with data obtained from control cells or tissues infected with the same (or a similar) virus, but not transfected with *fat-1*. The end point of these studies is the biochemical changes in cellular fatty acid composition and eicosanoid profile.

Cultures of virtually any animal cells (including human cell lines) can be infected with recombinant adenovirus (Ad.GFP.*fat-1* or Ad.GFP), after which expression of the transferred gene can be assessed by RNA or protein analysis. The experimental procedures and related methods are described in the Examples above and outlined in

Fig. 6. Various cell types including cardiac myocytes, neurons, hepatocytes, endothelial cells, and macrophages have been used in studies of n-3 fatty acids.

Cardiac myocytes can be isolated and cultured as described above (see Example 2), and other cell types, such as cerebellar granule neurons and hepatocytes can be prepared from 1-5 day-old rats following the method described by Schousboe *et al.* (*In A Dissection and Tissue Culture Manual of the Nervous System*, Shaha *et al.*, Eds., Alan R. Liss, New York, N.Y., pp. 203-206, 1989). Human cell lines, including breast cancer cell lines and leukemia cell lines can be cultured in MEN medium or RPMI 1640 supplemented with 10% fetal bovine serum (FBS) in a 37°C/5% CO₂ incubator.

Viral infection can be carried out by adding viral particles at various concentrations (*e.g.*, 2×10^9 – 2×10^{10} pfu) to culture medium containing no FBS or 2% FBS (*see also* Example 2). After a 24-hour incubation, the infection medium is replaced with normal (10% FBS) culture medium. Forty-eight hours after infection, cells can be used for analysis of gene expression or fatty acid composition. Transgene expression can be assessed by fluorescence microscopy when a fluorescent tag is included in the transgene (see Example 1 and Fig. 1; similarly, the tag can be an antigenic protein detected by a fluorescent antibody) or by a standard RNA assay (*e.g.* a Northern blot or RNase protection assay). Since the *fat-1* gene normally does not exist in control cells, it is not difficult to identify the difference in *fat-1* mRNA between the control cells and cells expressing *fat-1*.

n-3 desaturase catalyzes the introduction of an n-3 double bond into n-6 fatty acids, leading to formation of n-3 fatty acids with one more double bond than their precursor n-6 fatty acids (*e.g.*, $18:2n-6 \rightarrow 18:3n-3$, $20:4n-6 \rightarrow 20:5n-3$). The rate of conversion of substrates to products (the amount of products formed within a given time period) is thought to be directly proportional to the expression/activity of a desaturase. Thus, the functional activity of this enzyme can be determined, from a sample obtained from an animal (*e.g.*, a tissue sample) or in cultured cells by measurement of the conversions (the quantity of products) using the following methods.

Fatty acid desaturation assay using radiolabeled n-6 fatty acids as substrates: The assay can be performed following the protocol described by Kang *et al.* (*Biochim. Biophys Acta*. 1128:267-274, 1992). Briefly, various labeled n-6 fatty acids (*e.g.*,

[¹⁴C]18:2n-6, [¹⁴C]20:4n-6) bound to BSA are added to serum-free culture medium and incubated with cells for 4-6 hours. After that, cells and culture medium will be harvested. Lipids are extracted and methylated (see below). The labeled fatty acid methyl esters are separated according to degree of unsaturation (*i.e.*, the number of double bond) on silica-gel TLC plates impregnated with AgNO₃. Bands containing fatty acids with different double bonds can be identified by comparison with reference standards. Quantity of the labeled fatty acids is determined by scintillation counting, and data are compared between control cells and the cells expressing the *fat-1* gene.

Fatty acid analysis by gas chromatography: Conversion of fatty acids can be determined more accurately by analysis of fatty acid composition using gas chromatography-mass spectrometry (see below). Using this method, no radiolabeled fatty acid is required. Fatty acid contents of cultured cells expressing the n-3 desaturase gene, in the presence of various substrates, can be analyzed. The conversion of each fatty acid can be determined by comparison of fatty acid profiles between control cells and the cells expressing the *fat-1* gene.

The fatty acid composition of total cellular lipids or phospholipids can be analyzed as described previously (Kang *et al.*, *Biochim. Biophys. Acta.* 1128:267-274, 1992; Weylandt *et al.*, *Lipids* 31:977-982, 1996). The procedures are as follows:

Lipid extraction (see also Example 4): Five ml of chloroform/methanol (2:1, v/v) containing 0.005% butylated hydroxytoluene (as antioxidant) is added to washed cell pellets and vortexed vigorously for 1 minute then left at 4°C overnight. One ml of 0.88% NaCl is added and mixed again. The chloroform phase containing lipids is collected. The remains are extracted once again with 2 ml chloroform. The chloroform is pooled and dried under nitrogen and stored in sealed tubes at -70°C.

Separation of lipids by thin-layer chromatography (TLC): TLC plates are activated at 100°C for 60 minutes. TLC tanks are equilibrated with solvent for at least one hour prior to use. Total phospholipid and triacylglycerol are separated by running the sample on silica-gel G plates using a solvent system comprised of petroleum ether/diethyl ether/acetic acid (80:20:1 by vol.) for 30-35 minutes. Individual phospholipids are separated by TLC on silica-gel H plates using the following solvent system: chloroform/methanol/2-propanol/0.25% KCl/ triethylamine (30:9:25:6:18 by vol.).

Bands containing lipids are made visible with 0.01% 8-anilino-1-naphthalenesulfonic acid, and gel scrapings of each lipid fraction are collected for methylation.

Fatty acid methylation: Fatty acid methyl esters are prepared using 14% BF₃/methanol reagent. One or two ml of hexane and 1 ml of BF₃/methanol reagent are added to lipid samples in glass tubes with Teflon-lined caps. After being flushed with nitrogen, samples are heated at 100°C for one hour, cooled to room temperature and methyl esters are extracted in the hexane phase following addition of 1 ml H₂O. Samples are allowed to stand for 20-30 minutes, the upper hexane layer is removed and concentrated under nitrogen for GC analysis.

Gas chromatography-mass spectrometry. Methylated samples are reconstituted in 100-200 µl hexane or isooctane of which 1-2 µl will be analyzed by gas chromatography. An Omegawax column (30 m; Supelco, Bellefonte, PA) will be used in a Hewlett-Packard 5890A gas chromatograph (Hewlett-Packard, Avondage, PA). Carrier gas is hydrogen (2.39 ml/min), injected with a split ratio of 1:31. The temperature is initially 165°C for 5 minutes, then is increased to 195°C at 2.5°C/min and, from there, to 220°C at 5°C/min. The temperature is held for 10.5 minutes and then decreased to 165°C at 27.5°C/min. Peaks will be identified by comparison with fatty acid standards (Nu-Chek-Prep, Elysian, MN), and area percentage for all resolved peaks will be analyzed using a Perkin-Elmer M1 integrator (Perkin-Elmer, Norwood, CT). These analytical conditions separates all saturated, mono, di- and polyunsaturated fatty acids from C14 to C25 carbons in chain length. The sample size will be calculated based on external standards when added. In addition, the gas chromatography-mass spectrometry (GC-MS) will be carried out using a Hewlett-Packard mass selective detector (model 5972) operating at an ionization voltage of 70 eV with a scan range of 20-500 Da. The mass spectrum of any new peak obtained will be compared with that of standards (Nu Chek Prep, Elysian, MN) in the database NBS75K.L (National Bureau of Standards).

Example 7: Evaluation of n-3 desaturase gene transfer *in vivo*. The experiments described here allow introduction of the *fat-1* gene into animal tissues or organs (*e.g.*, heart), where the enzyme product can quickly optimize fatty acid profiles by increasing the content of n-3 PUFAs and decreasing the content of n-6 PUFAs. The heart

is selected as an experimental target for the gene transfer because it has been well studied in relation to n-3 fatty acids, and it is a vital organ.

Adult rats, fed a normal diet or a diet high in n-6 PUFA for two months, will be randomized to receive either an adenovirus carrying the fat-1 gene (Ad.GFP.fat-1) or an adenovirus carrying the reporter gene GFP (Ad.GFP, as control). The adenoviruses will be delivered to the heart of a living animal using a catheter-based technique, which can produce an expression pattern that is grossly homogeneous throughout the heart (Hajjar *et al.*, *Proc. Natl. Acad. Sci. USA* 95:525105256, 1998). Two days, 4 days, 10 days, 30 days and 60 days after infection (gene transfer), animals will be sacrificed, and their hearts will be harvested and used for determination of the transgene expression and analysis of fatty acid composition. Another group of rats will be fed a diet rich in n-3 fatty acids (low n-6/n-3 ratio) for two months without gene transfer and used as references. These experiments (in which animals are on different diets and samples harvested at different time points) are designed to determine whether transfer of the *fat-1* gene can bring about a desired biochemical effect (n-6/n-3 ratio, eicosanoid profile) similar to or even superior to that induced by dietary intervention (*i.e.*, n-3 FA supplementation), how quickly a significant change in fatty acid composition can be achieved, and how long the change can last. Rats injected with the reporter (GFP) gene will be used as controls (our preliminary studies showed that gene transfer of GFP has no effect on fatty acid composition). The experimental flow chart is shown in Fig. 7.

Animals and Diets: weight-matched adult Sprague-Dawley rats will be randomly assigned to three groups. Each group is fed with one of three different diets: normal (basal) diet, a high n-6 diet, or a high n-3 diet. These diets are prepared as follows.

Basal diet: a commercial rat fat-free diet (Agway Inc. C.G., Syracuse, NY) to which 2% (w/w) corn oil is added; *High n-6 diet:* the basal diet supplemented by addition of a further 13% (w/w) corn oil or safflower oil (high in n-6 fatty acids), bringing the final diet to a total of 15% fat; *High n-3 diet:* the basal diet supplemented with 13% (w/w) fish oil (30% EPA, 20% DHA, 65% total n-3 PUFA) (Pronova Biocare A/S, Oslo), bringing the final diet to a total of 15% fat. This group will serve as a control group for this study.

The diets will be prepared in small batches weekly, kept at -20° C and thawed

daily in the amounts required. Vitamin E (100mg/100g fat) and butylated hydroxy toluene (final concentration 0.05%) will be added to prevent oxidation of long-chain polyunsaturated fatty acids (The BHT should serve to prevent autooxidation of the unsaturated fatty acids during preparation and storage). To ensure animals are receiving adequate nutrition, the rats in all groups will be weighted weekly. After 8 weeks on the diets, the animals will be subjected to gene transfer.

Adenoviral Delivery Protocol. The delivery of adenoviruses to the heart will be performed by using a catheter-based technique similar to that described by Hajjar *et al* (*supra*). Briefly, rats will be anesthetized with intra peritoneal pentobarbital (60 mg/kg) and placed on a ventilator. The chest is entered from the left side through the third intercostals space. The pericardium is opened and a 7-0 suture placed at the apex of the left ventricle. The aorta and pulmonary artery are identified. A 22-gauge catheter containing 200 μ L adenovirus ($9-10 \times 10^{10}$ pfu/ml) is advanced from the apex of the left ventricle (LV) to the aortic root. The aorta and pulmonary arteries are clamped distal to the site of the catheter, and the solution is injected. The clamp is maintained for 10 seconds while the heart pumped against a closed system (isovolumically). After 10 seconds, the clamp on the aorta and pulmonary artery is released, the chest is closed, and the animals are extubated and transferred back to their cages.

At day 2, 4, 10, 30 and 60 after gene transfer, animals will be sacrificed, their hearts infected with the viruses will be removed, perfused or rinsed with saline to removed all blood and a portion of the tissues will be promptly frozen at -80°C for lipid analysis and eicosanoid measurement. The remaining tissues will be used for determination of the mRNA levels and/or protein levels of the n-3 desaturase.

It is possible that other organs such as brain and liver may also be infected at high levels by the adenoviruses entering the blood stream. Thus, other organs, in addition to the heart, will be also harvested for analyses of transgene expression and lipid profile.

Other methods, including assessment of transgene expression (by Northern blot, RNase protection assay, or *in situ* hybridization), analysis of fatty acid composition, measurement of eicosanoids, and statistical analysis will be carried out, as described above in the context of cultured cells.

Example 8: Transgenic animals.

The studies described here are designed to create transgenic mice that globally express the *fat-1* gene and to characterize the tissue and organ lipid profiles of these animals. Transgenic mice have become a valuable model for evaluation of physiological significance of a gene *in vivo*. Availability of transgenic mice allows us to study the effect of a transgene in a variety of cell types at different stages of an animal's lifespan. This n-3 transgenic mouse model will provide new opportunities to elucidate the roles of n-3 PUFA and compounds derived from them in the development and cell biology.

To generate transgenic animals that can globally express the *fat-1* gene, one can use an expression vector that contains a *fat-1* gene and the chicken beta-actin promotor with the CMV enhancer (CAG promotor), which is highly active in a wide range of cell types and therefore allows high-level and broad expression of the transgene (Niwa *et al.*, *Gene* 108:193-199, 1991; Okabe *et al.*, *FEBS Lett.* 407:313-319, 1997). The expression construct will be microinjected into the pronuclei of one-cell embryos of C57BL/6 X C3H mice to produce transgenic mice. They will be bred and transgenic mouse line is established. Weanling mice are fed either a normal diet or a diet high in n-6 PUFA. Various tissues will be harvested from these animals at different ages (neonate, wean --1 month, adult --6 ms and aging --12 ms, 3-5 mice per time point will be used) for assessment of the expression levels of the transgene and determination of fatty acid composition. The levels of eicosanoids in plasma and various tissues will also be measured. A group of wild-type mice (C57BL/6) fed with the same diet (either a normal diet or a high n-6 diet) will be used as controls. The results will be compared with those from wild type animals fed the same diet. The procedure is illustrated in Fig. 8.

The transgene will be prepared by methods similar to those described by Okabe *et al.* (*supra*). Briefly, a cDNA encoding the *fat-1* gene is amplified by PCR with primers, 5'-agaattcggcagcagccaa gtttgaggt-3' (SEQ ID NO:1) and 5'-gcctgaggctttatgcattcaacgcact-3' (SEQ ID NO:2), using pCE8-fat1 (provided by Dr. J. Browse, Washington State University) as a template. No additional amino acid sequence is added on either side of the *fat-1*. The PCR product will be confirmed by DNA sequencing. The *EcoR*I and *Bgl*-II sites included in the PCR primers are used to introduce the amplified *fat-1* cDNA into a pCAGGS expression vector containing the chicken beta-actin promoter and

cytomegalovirus enhancer, beta-actin intron and bovine globin poly-adenylation signal (provided by Dr. J Miyazaki, Osaka University Medical School). The entire insert with the promoter and coding sequence will be excised with *Bam*HI and *Sal*I and gel-purified.

Transgenic mouse lines will be produced by injecting the purified *Bam*HI and *Sal*I fragment into C57BL/6 X C3H fertilized eggs. The DNA-injected eggs are transplanted to pseudo-pregnant mice (B6C3F1) to produce transgenic mice. The founder transgenic mice will be identified by PCR and Southern blot analyses of tail DNA and bred with C57BL/6J mice. Offspring (either heterozygote or homozygote) will be used dependent on the expression levels of the transgene or phenotype.

Weanling transgenic mice will be fed either a normal diet or a diet high in n-6 PUFA (see above). Animals will be sacrificed at different ages (neonate, wean to 1 month, adult to 6 mos and aging –12 mos, 3-5 mice per time point will be used) and various tissues will be harvested for assessment of the expression level of transgene and determination of fatty acid composition. The results will be compared with those from wild type animals fed the same diet.

Other methods, including assessment of transgene expression (Northern blot, RNase protection assays, or *in situ* hybridization), analysis of fatty acid composition, measurement of eicosanoids, and statistical analyses will be carried out as described above.

In general accordance with the teaching provided above, we have made transgenic mice expressing the *C. elegans* fat-1 gene encoding an n-3 fatty acid desaturase. These mice are capable of producing n-3 from n-6 fatty acids, leading to enrichment of n-3 fatty acids with reduced levels of n-6 fatty acids in almost all organs and tissues, including muscles and milk, with no need of dietary n-3 fatty acid supply. This achievement supports our theory that such animals (*i.e.*, any animal that effectively expresses or overexpresses the product of a fat-1 nucleic acid sequence) are unique research tools and a new and ideal source of n-3 fatty acids that can be used to meet the nutritional needs of humans and other animals.

To heterologously express the *C. elegans* n-3 fatty acid desaturase in mice, the *fat-1* gene encoding this protein was modified from the original by optimization of codon usage for mammalian cells and coupled to a chicken beta-actin promoter and

cytomegalovirus enhancer, which are highly active in a wide range of cell types and therefore allows high-level and broad expression of transgene in mice (Niwa *et al.*, *Gene* 108:193-199, 1991; Okabe *et al.*, *FEBS Lett.* 407:313-319, 1997).

The expression of the *fat-1* in F1 pups from transgenic founder mice and their offspring was examined by Real-Time PCR of tail DNA and by analysis of tail lipids. The transgenic mice looked normal and very healthy. Both transgenic and wild type mice were maintained at a diet high in omega-6 fatty acids (mainly linoleic acid) with very little omega-3 fatty acids (~0.1% of total fat supplied). Feeding this n-3 depleted diet allowed us to readily identify the phenotype. Under this dietary regime, wild-type mice have little or no n-3 fatty acid in their tissues because the animals naturally cannot produce n-3 from n-6 fatty acids, whereas the *fat-1* transgenic mice should have appreciable amounts of n-3 fatty acids (derived from n-6 fatty acids) in their tissues if the transgene is functional *in vivo*.

Since the phenotype of the transgenic mouse lines is mainly reflected by lipid profiles, we analyzed the fatty acid composition of various organs of the transgenic mice at different ages by gas chromatography-mass spectrometer.

Interestingly, the muscle of the transgenic animals has the most significant changes in these ratios, indicating the highest enzyme activity in this tissue. To date, four generations (either homozygotes or heterozygotes) of transgenic mouse lines have been examined and their tissue fatty acid profiles showed consistently high levels of n-3 fatty acids, indicating the transgene is functionally active *in vivo* and transmittable. Our data clearly show that the transgenic mice expressing the *fat-1* gene are capable of producing n-3 fatty acids from n-6 fatty acids, resulting in enrichment of n-3 fatty acids in their organs /tissues without the need of dietary n-3 supply, which is impossible in wild type mammals.

Our findings provide a new strategy for producing n-3 PUFA-enriched foodstuff (*e.g.* meat, milk and eggs) by generating large transgenic animals (*e.g.* cow, pig, sheep, goat, rabbit, deer, chicken and other fowl (*e.g.*, goose, duck, pheasant, and game hen) with the n-3 desaturase gene.

The methods used to generate the animals are described in more detail below.

Expression Vectors: The cDNA encoding the n-3 fatty acid desaturase was synthesized based on the sequence of *fat-1* cloned from *C. elegans* (Spychalla, *et al.*, *Proc. Natl. Acad. Sci. USA* 94:1142-1147, 1997) with modification of codon usage using mouse codon frequencies as reference. The synthesized fat-1 cDNA was confirmed by DNA sequencing and then cloned into a pCAGGS expression vector containing the chicken β -actin promoter and cytomegalovirus enhancer, beta-actin intron and bovine globin poly-adenylation signal. The entire insert with the promoter and coding sequence was excised with *Ssp* I and *Sfi* I and gel-purified.

Production of Transgenic Mice. Transgenic mouse lines were produced by injecting the purified *Ssp* I and *Sfi* I fragment into C57BL/6 X C3H fertilized eggs. The DNA-injected eggs were transplanted to pseudo-pregnant mice (B6C3F1) to produce transgenic mice. The founder transgenic mice were identified by Real-Time PCR of tail DNA and lipid analysis of tail tissues and bred with C57BL/6J mice. We obtained seven transgenic founders. Three of them were selected to sire transgenic lines. Each has had three generations to date.

Animal feeding. Both transgenic and wild type (C57BL/6J) mice were maintained at an AIN-76A based Rodent diet containing 5% (w/w) of safflower oil. The fatty acid composition of safflower oil is as follows: 10% saturated fatty acids, 14% monounsaturated fatty acids, 76% n-6 polyunsaturated linoleic acid and ~0.1% n-3 polyunsaturated alpha-linolenic acid.

1. *Lipid Analysis.* The fatty acid composition of total tissue lipids was analyzed as described previously (Kang *et al.*, *Biochim. Biophys. Acta.* 1128:267-274, 1992). Lipid was extracted with chloroform/methanol (2:1, v/v) containing 0.005% butylated hydroxytoluene (as antioxidant). Fatty acid methyl esters were prepared using a 14% BF_3 /methanol reagent. Fatty acid methyl esters were analyzed by gas chromatography using a fully automated HP5890 system equipped with a flame-ionization detector. The chromatography utilized an Omegawax 250 capillary column (30 m x 0.25 mm I.D.). The oven program is initially

maintained at 180 °C for 5 min, then ramped to 200 °C at 2 °C/min and held for 48 minutes. Peaks were identified by comparison with fatty acid standards (Nu-chek-Prep, Elysian, MN), and area percentage for all resolved peaks was analyzed using a Perkin-Elmer M1 integrator. Fatty acid mass is determined by comparing areas of various analyzed fatty acids to that of a fixed concentration of external standard when added.

Table 1. Comparison of the n-6/n-3 ratios and AA/(EPA+DPA+DHA) ratio in various organs and tissues between a wild type mouse (WT) and a *fat-1* transgenic mouse (TG)*.

| | Omega-6/Omega-3** | | AA/(EPA+DPA+DHA) | |
|---------|-------------------|-----|------------------|-----|
| | WT | TG | WT | TG |
| Muscle | 49.0 | 0.7 | 11.3 | 0.4 |
| Milk*** | 32.7 | 5.7 | 15.7 | 2.5 |
| RBC | 46.6 | 2.9 | 27.0 | 1.6 |
| Heart | 22.8 | 1.8 | 14.3 | 0.9 |
| Brain | 3.9 | 0.8 | 3.6 | 0.7 |
| Liver | 26.0 | 2.5 | 12.5 | 0.9 |
| Kidney | 16.5 | 1.7 | 11.9 | 1.2 |
| Lung | 32.3 | 2.2 | 19.8 | 1.2 |
| Spleen | 23.8 | 2.4 | 17.3 | 1.5 |

*Both the wild-type and transgenic mice were 8 weeks old female and fed with the same diet.

**The n-6/n-3 fatty acid ratio is $(18:2n-6 + 20:4n-6 + 22:4n-6 + 22:5n-6)/(18:3n-3 + 20:5n-3 + 22:5n-3 + 22:6n-3)$.

***The milk was taken from the content of stomachs of 5-day neonatal mice born from a wild type or a transgenic mother.

Example 9: Inhibition of neuronal cell death

Construction of Recombinant Adenovirus (Ad): A recombinant Ad carrying the

fat-1 gene was constructed as described previously (Kang *et al.*, *Proc. Natl. Acad. Sci. USA* 98;4050-4054, 2001; *see also*, above). The n-3 fatty acid desaturase cDNA (*fat-1* gene) used was that described above, provided in plasmid pCE8. The *fat-1* cDNA was excised from the plasmid with an *EcoRI/KpnI* digestion, and inserted into pAdTrack-CMV vector. The construct was subsequently recombined homologously with an adenoviral backbone vector (pAdEasy 1) to generate two clones: Ad-GFP, which expresses GFP as a reporter or marker, and Ad-GFP-*fat-1*, which carries both the *fat-1* and the GFP genes, each under the control of separate CMV promoters. Recombinant adenoviral vector DNA was digested with *PacI*. The linearized vector DNA was mixed with SuperFect™ (QIAGEN) and used to infect 293 cells. The recombinant viruses were prepared as high-titer stocks through propagation in 293 cells. The integrity of the constructs was confirmed by enzymatic digestion (*i.e.*, restriction mapping) and by DNA sequencing. Purified virus was checked and its sequence confirmed again by PCR analysis.

Tissue Culture and Infection with Ad: Rat cortical neurons were prepared using standard techniques. Briefly, prenatal embryonic day 17 (E17) rat cortical neurons were dissociated and plated in poly-lysine-coated wells at 2×10^6 cells/well. The cells were grown in Neurobasal™ Medium (NBM, Life Technologies) supplemented with 25 mM glutamic acid (Sigma Chemical Co., St. Louis, MO), 0.5 mM glutamine, 1% antibiotic-antimycotic solution, and 2% B27 (Life Technologies). Cultures were kept at 37°C in air with 5% CO₂ and 98% relative humidity. The culture medium was changed every four days. After 8-10 days in culture, cells were transfected with either the Ad-GFP (control) or the Ad-GFP-*fat-1* plasmids. Viral infections were carried out by adding viral particles to the culture medium. After a 48-hour incubation, cells were used for analyses of gene expression, fatty acid composition, eicosanoid production, and induction of apoptosis.

RNA Analysis: The level of *fat-1* expression was determined by probing for mRNA transcripts in an RNase protection assay using the RPA III™ kit (Ambion, Austin, TX). Briefly, total RNA was extracted from cultured cells using a total RNA isolation reagent (TRIzol, GIBco BRL) according to the manufacturer's protocol. The plasmid containing the *fat-1* gene, pCE8, was linearized and used as a transcription template. Antisense RNA probes were transcribed *in vitro* using [³³P]-UTP, T7

polymerase (Riboprobe System™ T7 kit, Promega), hybridized with total RNA (15 µg) extracted from neurons, and digested with ribonuclease to remove nonhybridized RNA and probe. The protected RNA-RNA hybrids were resolved in a denaturing 5% sequence gel and subjected to autoradiography. A probe targeting the β -actin gene was used as an internal control. *fat-1* mRNA was not detected in cells infected with Ad-GFP (control), but was highly abundant in cells infected with Ad-GFP-*fat-1*.

The cells were also examined by fluorescence microscopy. Infected cells that expressed the *fat-1* gene were readily identifiable because they co-expressed GFP. Forty-eight hours after infection, 30-40% of the neurons were infected and expressed GFP. These results demonstrate that Ad-mediated gene transfer confers high expression of *fat-1* gene in rat cortical neurons, which normally lack the gene.

Lipid Analysis: The fatty acid composition of total cellular lipids was analyzed as described in Kang *et al.* (*Proc. Natl. Acad. Sci. USA* 98:4050-4054, 2001). Lipid was extracted with chloroform:methanol (2:1, vol:vol) containing 0.005% butylated hydroxytoluene (BHT, as an antioxidant). Fatty acid methyl esters were prepared using a 14% (wt/vol) BF₃/methanol reagent. Fatty acid methyl esters were quantified with GC/MS by using an HP-5890 Series II gas chromatograph equipped with a Supelcowax™ SP-10 capillary column (Supelco, Bellefonte, PA) attached to an HP-5971 mass spectrometer. The injector and detector are maintained at 260°C and 280°C, respectively. The oven program is maintained initially at 150°C for 2 minutes, then ramped to 200°C at 10°C/minute and held for 4 minutes, ramped again at 5°C/minute to 240°C, held for 3 minutes, and finally ramped to 270°C at 10°C/minute and maintained for 5 minutes. Carrier gas-flow rate is maintained at a constant 0.8 ml/min throughout. Total ion monitoring is performed, encompassing mass ranges from 50-550 atomic mass units. Fatty acid mass is determined by comparing areas of various analyzed fatty acids to that of a fixed concentration of internal standard.

The expression of *fat-1* resulted in conversion of n-6 fatty acids to n-3 fatty acids, and thus a significant change in the ratio of n-6:n-3 fatty acids. The fatty acid profile obtained from control cells is significantly different from that of cells infected with Ad-GFP-*fat-1* (Fig. 9; see also Fig. 10). Cells infected with Ad-GFP show no change in fatty acid composition when compared with non-infected cells. In cells expressing the n-3

desaturase, almost all types of n-6 fatty acids were converted to the corresponding n-3 fatty acids, namely, 18:2n-6 to 18:3n-3, 20:4n-6 to 20:5n-3, 22:4n-6 to 22:5n-3, and 22:5n-6 to 22:6n-3. The change in fatty acid composition of the cells expressing the *fat-1* gene resulted in reduction of the n-6:n-3 ratio from 6.4:1 in the control cells to 1.7:1 in the cells expressing the n-3 desaturase. Expression of the *C. elegans* n-3 fatty acid desaturase resulted in a significant increase in the levels of DHA in transfected cells. An increase in levels of EPA and ALA is observed with a concomitant decrease in AA and LA suggesting that the decrease in production of PGE₂ resulted from both the shift in the n-6:n-3 fatty acid ratio and from DHA-mediated inhibition of AA hydrolysis.

Measurement of Eicosanoids: 2-series eicosanoids may be associated with neuronal apoptosis in age-associated neurodegenerative diseases and acute excitotoxic insults such as ischemia (Sanzgiri *et al.*, *J. Neurobiol.* 41:221-229, 1999; Drachman and Rothstein, *Ann. Neurol.* 48:792-795, 2000; Bezzi *et al.*, *Nature* 391:281-285, 1998). Arachidonic acid (AA, 20:4n-6) and eicosapentaenoic acid (EPA, 20:5n-3) are the precursors of 2- and 3-series of eicosanoids, respectively. To determine whether the gene transfer-mediated alteration in the contents of AA and EPA may lead to a difference in the production of eicosanoids in the cells, we measured the production of prostaglandin E₂, one of the major eicosanoids derived from AA, in infected cells after stimulation with calcium ionophore A23187. More specifically, prostaglandin E₂ was measured by using enzyme immunoassay kits (Cayman Chemical, Ann Arbor, MI) following the manufacturer's protocol. (The crossreactivity with prostaglandin E₃ is 16%.) Cultured cells were washed with LH buffer (with 1% BSA) and incubated with the same buffer containing the calcium ionophore A23187 (5 μ M). After a 10-minute incubation, the conditioned buffer was recovered and subjected to eicosanoid measurement. The amount of prostaglandin E₂ produced by *fat-1* expressing cells was 20% lower than that produced by control cells (Fig. 11).

Induction of apoptosis and determination of cell growth and viability: Apoptosis was induced by growth factor withdrawal. Forty-eight hours after neurons were transfected, the culture media was changed to Neurobasal™ Medium supplemented with 25 mM glutamic acid (Sigma Chemical Co., St. Louis, MO) and 0.5 mM glutamine. Cytotoxicity was measured 24 hours after growth factors were withdrawn using the

Vybrant™ Apoptosis Assay (Molecular Probes, Eugene, OR). Briefly, cells were washed with ice-cold phosphate buffered saline (PBS) and subsequently incubated on ice for 20-30 min in ice-cold PBS containing Hoechst 33342 solution (1 ml/ml) and PI solution (1 ml/ml). A photograph was taken at the end of the incubation period.

Cell growth and viability: Cell growth and viability were determined using the MTT cell proliferation kit (Roche Diagnostic Corporation). MTT labeling reagent (100 μ l) was added to each well. After 4 hours of incubation, 1.0 ml of the solubilization solution was added into each well. The cells were then incubated overnight at 37°C and the spectrophotometrical absorbency of the solution at 600 nm was measured.

Expression of the *fat-1* gene provided strong protection against apoptosis in rat cortical neurons. Hoest 33625 and PI staining of cortical cultures 24 hours after the induction of apoptosis, show that cultures infected with Ad-GFP-*fat-1* underwent less apoptosis than those infected with Ad-GFP. MTT analysis indicated that the viability of Ad-GFP-*fat-1* cells was significantly ($p<0.05$) higher than that of cells infected with Ad-GFP (Fig. 12). These results indicate that the expression of *fat-1* can inhibit neuronal apoptosis and promote cell viability. The ability of the *C. elegans* n-3 fatty acid desaturase to inhibit apoptosis of neuronal cells highlights the importance of the n-6:n-3 fatty acid ratio in neuroprotection. Accordingly, techniques that deliver a *fat-1* sequence, or a biologically active variant thereof, to neurons provide the means to quickly and dramatically balance cellular n-6:n-3 fatty acid ratio, alter eicosanoid profile (and thereby exert an anti-apoptotic effect on neuronal cells) without the need for supplementation with exogenous n-3 PUFAs. Compared to dietary intervention, this approach is more effective in balancing the n-6:n-3 ratio because it simultaneously elevates the tissue concentration of n-3 PUFAs and reduces the level of endogenous n-6 PUFAs. This method is a novel and effective approach to modifying fatty acid composition in neuronal cells, and it can be applied as a stand-alone gene therapy or as an adjuvant therapy or chemopreventive procedure (in, for example, apoplexy patients).

Data analysis, statistical analysis: Cell viability data (MTT), as well as fatty acid composition and eicosanoids levels were compared using the Student t-test. The analysis included 6 wells/group (except lipid analyses; 4 wells/group) and each experiment was repeated 3 times. The level of significance was set at $p<0.05$.

Example 10: *fat-1* expression in human endothelium and inhibition of inflammation

To determine whether the conversion of n-6 to n-3 PUFA can be genetically conferred to primary human vascular endothelium and to study its potential protective effects against endothelial activation after cytokine stimulation, a first generation (type 5) recombinant adenoviral vector (Ad) was constructed which contained the *fat-1* transgene in series with a GFP expression cassette under the control of the CMV promoter (Ad.*fat-1*). A GFP/ β -gal adenovirus served as the control vector (Ad.GFP/ β -gal). Monolayers of primary human umbilical vein endothelial cells (HUVECs) were infected with Ad.*fat-1* or the control Ad for 36 hours, exposed for 24 hours to 10 mM arachidonic acid, and subjected to lipid analysis by gas chromatography, surface adhesion molecule analysis by immunoassay, and videomicroscopy to study endothelial interactions with the monocytic cell line, THP-1, under laminar flow conditions.

Expression of *fat-1* dramatically altered the lipid composition of human endothelial cells and changed the overall ratio of n-6 to n-3 PUFA from 8.5 to 1.4. Furthermore, after cytokine exposure (TNF- α , 5 μ /ml applied for 4 hours) *fat-1* expression significantly reduced the surface expression of the adhesion molecules and markers of inflammation (E-Selectin, ICAM-1, and VCAM-1 by 42%, 43%, and 57%, respectively ($p < 0.001$)).

We then asked whether changes in the adhesion molecule profile were sufficient to alter endothelial interactions with monocytes, the most prevalent white blood cell type found in atherosclerotic lesions. Under laminar flow and a defined shear stress of ~ 2 dynes/cm², *fat-1*-infected HUVEC, compared to control vector-infected HUVEC, supported $\sim 50\%$ less firm adhesion with almost no effect on the rolling interactions of THP-1 cells. Thus, heterologous expression of the *C. elegans* desaturase, *fat-1*, confers on human endothelial cells the ability to convert n-6 to n-3 PUFA. This effect significantly repressed cytokine induction of the endothelial inflammatory response and firm adhesion of the monocytic cell line, THP-1, under simulated physiological flow conditions. Accordingly, expression of *fat-1* represents a potential therapeutic approach to treating inflammatory vascular diseases, such as atherosclerosis.

Example 11: n-3 desaturase as an anti-arrhythmic agent

To determine whether *fat-1* expression could provide an anti-arrhythmic effect, myocytes expressing the n-3 desaturase were examined for their susceptibility to arrhythmias induced by arrhythmogenic agents. Neonatal rat cardiac myocytes, grown on glass coverslips and able to spontaneously beat, were infected with Ad.GFP.fat-1 or Ad.GFP. Two days after infection, cells were transferred to a perfusion system and perfused with serum free medium containing high concentrations (5-10 mM) of calcium. These media are arrhythmogenic. During the perfusion process, myocyte contraction was monitored using a phase contrast microscope and video-monitor edge-detector. Following the high $[Ca^{2+}]$ (7.5 mM) challenge, the control cells infected with Ad.GFP promptly exhibited an increased beating rate followed by spasmodic contractions or fibrillation whereas the cells infected with Ad.GFP.fat-1 could sustain regular beating. Thus, myocytes expressing the n-3 desaturase show little, if any, susceptibility to arrhythmogenic stimuli (Fig. 13).

Example 12: *fat-1* expression and inhibition of tumor growth

To test the effect of the gene transfer on tumor growth *in vivo*, we have carried out a pilot experiment in two nude mice bearing human breast cancer xenografts (MDA-MB-231). One mouse was injected intratumorally with 50µl of Ad.GFP.fat-1 (1012 particles/µl) twice every other day. The other was injected with the control vector (Ad.GFP). The growth rate of the tumors was monitored for four weeks. The growth rate of the tumor treated with Ad.GFP.fat-1 appeared to be slower than that of the control tumor (Fig. 14).

Example 13: The effect of *fat-1* expression on fatty acid composition and growth of human breast cancer cells in culture

Construction of Recombinant Adenovirus (Ad): A recombinant Ad carrying the *fat-1* cDNA was constructed as described previously (Kang *et al.*, *Proc. Natl. Acad. Sci. USA* 98:4050-4054, 2001). Briefly, the *fat-1* cDNA in pCE8 (as described above) was excised from the plasmid with an *EcoRI/KpnI* double digest, inserted into a shutter vector and then subjected to homologous recombination with an adenoviral backbone according to the methods of He *et al.* (*Proc. Natl. Acad. Sci. USA* 95:2509-2514, 1998). Two first-generation type 5 recombinant adenoviruses were generated: Ad.GFP, which carries GFP as a reporter gene under control of the CMV promoter, and Ad.GFP.*fat-1*, which carries both the *fat-1* and GFP genes, each under the control of separate CMV promoters. The recombinant viruses were prepared as high titer stocks through propagation in 293 cells, as described previously (Kang *et al.*, *Proc. Natl. Acad. Sci. USA* 98:4050-4054, 2001). The integrity of the constructs was confirmed by enzymatic digestion and by DNA sequence analysis.

Cell Cultures and Infection with Ad.: MCF-7 cells were routinely maintained in 1:1 (v/v) mixture of DMEM and Ham's F12 medium (JRH, Bioscience) supplemented with 5% fetal bovine serum (FBS) plus antibiotic solution (penicillin, 50 U/ml; streptomycin, 50 µg/ml) at 37°C in a tissue culture incubator with 5% CO₂ and 98% relative humidity. Cells were infected with Ad for experiments when they were grown to about 70% confluence by adding virus particles to medium without serum (3-5 x10⁸ particles/ml). Initially, optimal viral concentration was determined by using Ad.GFP to achieve an optimal balance of high gene expression and low viral titer to minimize cytotoxicity. After a 24-hour incubation, the infection medium was replaced with normal culture medium supplemented with 10 µM 18:2n6 and 20:4n6. Forty-eight hours after infection, cells were used for analyses of gene expression, fatty acid composition, eicosanoid production, and cell proliferation and apoptosis.

RNA Analysis: The *fat-1* transcripts were examined by ribonuclease protection assay using a RPA IIITM kit (Ambion, Austin, TX). Briefly, total RNA was extracted from cultured cells using a RNA isolation kit (Qiagen) according to the manufacturer's protocol. The plasmid containing *fat-1*, pCE8, was linearized and used as transcription

template. Antisense RNA probes were transcribed *in vitro* using ^{33}P -UTP and T7 polymerase (Riboprobe™ System T7 kit, Promega), hybridized with the total RNA extracted from the cancer cells, and digested with RNase to remove non-hybridized RNA and probe. The protected RNA:RNA was resolved in denaturing sequence gel and subjected to autoradiography. A probe targeting the GAPDH gene was used as an internal control.

The cells that were infected and expressed the transgene could be readily identified by fluorescence microscopy since they co-expressed the GFP (which exhibits bright fluorescence). Three days after infection, it was observed that about 60-70 percent of the cells were infected and expressed the transgene. Analysis of mRNA using a ribonuclease protection assay showed that *fat-1* mRNA was highly abundant in cells infected with Ad.GFP.fat-1, but was not detected in cells infected with Ad.GFP (control). This result indicates that the Ad-mediated gene transfer could confer a high expression of fat-1 gene in MCF-7 cells, which normally lack the gene.

Lipid Analysis: To examine the efficacy of the gene transfer in modifying the fatty acid composition of the human MCF-7 cells, total cellular lipids were extracted and analyzed by gas chromatograph after infection with the Ads and incubation with n-6 fatty acids for 2-3 days. The fatty acid composition of total cellular lipids was analyzed as described (Kang *et al.*, *supra*). Lipid was extracted with chloroform/methanol (2:1, vol/vol) containing 0.005% butylated hydroxytoluene (BHT, as antioxidant). Fatty acid methyl esters were prepared by using a 14% (wt/vol) BF₃/methanol reagent. Fatty acid methyl esters were quantified with GC/MS by using an HP-5890 Series II gas chromatograph equipped with a Supelcowax SP-10 capillary column (Supelco, Bellefonte, PA) attached to an HP-5971 mass spectrometer. The injector and detector are maintained at 260°C and 280°C, respectively. The oven program is maintained initially at 150°C for 2 min, then ramped to 200°C at 10°C/min and held for 4 min, ramped again at 5°C/min to 240°C, held for 3 min, and finally ramped to 270°C at 10°C/min and maintained for 5 min. Carrier gas-flow rate is maintained at a constant 0.8 ml/min throughout. Total ion monitoring is performed, encompassing mass ranges from 50-550 atomic mass units. Fatty acid mass is determined by comparing areas of various analyzed fatty acids to that of a fixed concentration of internal standard.

The expression of fat-1 cDNA in MCF-7 cells resulted in conversions of n-6 fatty acids to n-3 fatty acids, and a significant change in the ratio of n-6/n-3 fatty acids. The fatty acid profiles are remarkably different between the control cells infected just with the Ad.GFP and the cells infected with the Ad.GFP.fat-1 (Fig. 15). Cells infected with Ad.GFP had no change in their fatty acid profiles when compared with noninfected cells. In the cells expressing the fat-1 cDNA (n-3 fatty acid desaturase), various n-6 fatty acids were converted largely to the corresponding n3 fatty acids, for example, 18:2n6 to 18:3n3, 20:4n6 to 20:5n3, and 22:4n6 to 22:5n3. As a result, the fatty acid composition of the cells expressing fat-1 gene was changed significantly when compared with that of the control cells infected with Ad.GFP (Fig. 15), with a large reduction of the n-6/n-3 ratio from 12 in the control cells to 0.8 in the cells expressing the n-3 fatty acid desaturase.

Measurement of Eicosanoids: It has been shown previously that prostaglandin E₂ (PGE₂), one of the major eicosanoids derived from 20:4n6 (arachidonic acid), is associated with cancer development (Rose and Connolly, Pharmacol. Ther. 83:217-244, 1999; Cave, Breast Cancer Res. Treat. 46:239-246, 1997). To determine whether the gene transfer-induced alteration in the contents of arachidonic and eicosapentaenoic acids can change the production of eicosanoids in the cells, we measured the production of PGE₂ in the infected cells after stimulation with calcium ionophore A23187 by using an enzyme immunoassay kit that specifically detects prostaglandin E₂ derived from AA with a 16% crossreactivity with prostaglandin E₃ from EPA. More specifically, prostaglandin E₂ was measured by using enzyme immunoassay kits (Assay Designs, Inc) following the manufacturer's protocol. (The cross-reactivity with PGE₃ is 16%). Cultured cells were washed with PBS containing 1% BSA and incubated with serum-free medium containing calcium ionophore A23187 (5 μ M). After a 10-minute incubation, the conditioned medium was recovered and subjected to eicosanoid measurement. The amount of prostaglandin E₂ produced by the fat-1 cells was significantly lower than that produced by the control cells (Fig. 16).

Analysis of Cell Proliferation and Apoptosis: To determine the effect of expression of the fat-1 gene on MCF-7 cell growth, cell proliferation and apoptosis following gene transfer were assessed. Routinely, cell morphology was examined by

microscopy (dead cells appear to be detached, round and small) and total number of cell in each well was determined by counting the viable cells using a hemocytometer. In addition, cell proliferation was assessed using a MTT Proliferation Kit I (Roche Diagnostics Corporation). Apoptotic cells were determined by nuclear staining with Vybrant™ Apoptosis Kit #5 (Molecular Probes) following the manufacturer's protocol.

A large number of the cells expressing fat-1 gene underwent apoptosis, as indicated by morphological changes (small size with round shape or fragmentation) and nuclear staining (bright blue). Statistic analysis of apoptotic cell counts showed that 30-50% of cells infected with Ad.GFP.fat-1 were apoptotic whereas only 10% dead cells found in the control cells (infected with Ad.GFP). MTT analysis indicated that proliferative activity of cells infected with Ad.GFP.fat-1 was significantly lower than that of cells infected with Ad.GFP. Accordingly, the total number of viable cells in the cells infected with Ad.GFP.fat-1 was about 30% less than that in the control cells. These results are consistent with the proposition that fat-1 expression can serve as an anti-cancer agent.

Data analyses, statistical analyses: Data were presented as mean \pm SE. Student's T test was used to evaluate the difference between two values. The level of significance was set at $p < 0.05$. Results

A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention.

Additional references: Simopoulos and Cleland, *World Rev. Nutr. Diet* (Basel, Karger) Vol. 92, 2003; Simopoulos *et al.* (Eds). *World. Rev. Nutr. Diet.* (Basel, Karger) Vol. 83, 1998; Connor, *Am. J. Clin. Nutr.* 71:171S-175S, 2000, Simopoulos, *Am. J. Clin. Nutr.* 70:560S-569S, 1999; Salem *et al.*, *Lipids* 31:S1-S326, 1996; Leaf and Weber, *Am. J. Clin. Nutr.* 45:1048-1053, 1987; and Simopoulos, *Poultry Sci.* 79:961-970, 2000.

What is claimed is:

1. An isolated nucleic acid molecule comprising a first and a second nucleic acid sequence, wherein the first sequence encodes an enzyme that desaturates an ω -6 fatty acid to a corresponding ω -3 fatty acid and the second sequence is a tissue-specific promoter that directs expression of the first sequence in a selected mammalian cell type.
2. The nucleic acid molecule of claim 1, wherein the mammalian cell type is a myocyte, endothelial cell, adipose cell, or neuron.
3. The nucleic acid molecule of claim 1, wherein the mammalian cell type is a type of cancer cell.
4. An expression vector comprising the nucleic acid molecule of claim 1.
5. A mammalian cell comprising the vector of claim 4.
6. A transgenic mammal comprising the cDNA sequence shown in Fig. 17A, or a biologically active fragment or mutant thereof.
7. A method of improving the content of ω -3 fatty acids in a patient's diet, the method comprising providing to the patient a food product obtained from a transgenic mammal that expresses a *fat-1* gene of a non-mammalian animal, or a biologically active fragment or variant thereof.
8. A method of treating a patient who has cancer, the method comprising administering to the patient a therapeutically effective amount of the nucleic acid molecule of claim 1, wherein the tissue-specific promoter directs expression of the sequence encoding the enzyme in the patient's cancerous cells.

9. The method of claim 8, wherein the cancerous cells are breast cancer cells or colon cancer cells.
10. A method of inhibiting neuronal cell death in a patient, the method comprising administering to the patient a therapeutically effective amount of the nucleic acid molecule of claim 1, wherein the tissue-specific promoter directs expression of the sequence encoding the enzyme in neurons.
11. The method of claim 10, wherein the patient has a neurodegenerative disease.
12. The method of claim 11, wherein the neurodegenerative disease is Alzheimer's disease, Parkinson's disease, or Huntington's disease.
13. A method of treating a patient who has, or who may develop, a condition associated with an insufficiency of n-3 polyunsaturated fatty acid (PUFA) or an imbalance in the ratio of n-3:n-6 PUFAs, the method comprising administering to the patient a nucleic acid encoding an n-3 desaturase or a biologically active variant thereof.
14. The method of claim 13, wherein the condition is an arrhythmia, cardiovascular disease, cancer, an inflammatory disease, an autoimmune diseases, a malformation or threatened malformation of the retina or brain, diabetes, obesity, a skin disorder, a renal disease, ulcerative colitis, Crohn's disease, or chronic obstructive pulmonary disease.
15. A method of treating a patient who has received, or who is scheduled to receive, a transplant comprising a biological organ, tissue, or cell, the method comprising administering to either the patient or to the transplant, a nucleic acid encoding an n-3 desaturase or a biologically active variant thereof.
16. An isolated nucleic acid molecule comprising a *C. elegans fat-1* nucleic acid comprising at least one optimized codon.

17. The isolated nucleic acid molecule of claim 16, wherein at least 5 and up to 150 codons differ from the codons in the corresponding wild type *C. elegans fat-1* nucleic acid sequence, yet encode the same amino acid residue as is found in the corresponding position in the wild-type *C. elegans fat-1* amino acid sequence.

18. The isolated nucleic acid molecule of claim 17, wherein 5-10, 10-15, 15-20, 20-25, 25-30, 30-35, 35-40, 40-45, 45-50, 50-55, 55-60, 60-65, 65-70, 70-75, 75-80, 80-85, 85-90, 90-95, 95-100, 100-105, 105-110, 110-115, 115-120, 120-125, 125-130, 130-135, 135-140, 140-145, or 145-150 of the codons of the wild-type *C. elegans fat-1* nucleic acid sequence are optimized.

19. The isolated nucleic acid of any of claims 16-18, comprising an optimized codon at position 6, 9, 18, 20, 22, 24, 28-30, 33-36, 47, 49, 52, 54, 58, 60, 61, 64, 67, 69-71, 73, 77, 79, 81, 86, 89, 92, 94-95, 100, 101, 105, 106, 112, 115, 118, 124, 127, 128, 131, 146, 151, 154, 161, 163, 164, 169, 178, 187, 188, 195, 197, 200, 202, 206, 210, 214, 217, 221, 223, 225, 227, 228, 232, 234, 241, 245, 255, 271, 280-282, 284, 285, 301, 303, 310, 312, 327, 362, or 370.

20. The isolated nucleic acid of any of claim 16-18, comprising the sequence of the nucleic acid shown in Fig. 18.

ABSTRACT

The present invention features compositions (*e.g.*, nucleic acids encoding *fat-1*, optionally and operably linked to a constitutively active or tissue-specific promoter or other regulatory sequence and pharmaceutically acceptable formulations including that nucleic acid or biologically active variants thereof) and methods that can be used to effectively modify the content of PUFAs in animal cells (*i.e.*, cells other than those of *C. elegans*, for example, mammalian cells such as myocytes, neurons (whether of the peripheral or central nervous system), adipocytes, endothelial cells, and cancer cells). The modified cells, whether *in vivo* or *ex vivo* (*e.g.*, in tissue culture), transgenic animals containing them, and food products obtained from those animals (*e.g.*, meat or other edible parts of the animals (*e.g.*, liver, kidney, or sweetbreads)) are also within the scope of the present invention.

20800734.doc




Fig. 1

BEST AVAILABLE COPY



Fig. 2

BEST AVAILABLE COPY




Fig. 3




Fig. 4

| Mol % of total Fatty acids | Control | Fat-1 |
|-------------------------------|-------------------------|------------------------|
| n-6 Polyunsaturates | | |
| 18:2n-6 | 14.2 ^a | 9.2 ^b |
| 20:2n-6 | 1.2 ^a | 0.3 ^b |
| 20:3n-6 | 1.6 ^a | 0.4 ^b |
| 20:4n-6 | 15.2 ^a | 4.1 ^b |
| 22:4n-6 | 4.4 ^a | 1.0 ^b |
| 22:5n-6 | 0.2 ^a | 0.0 ^b |
| Total | 36.8 ^a | 15.0 ^b |
| n-3 Polyunsaturates | | |
| 18:3n-3 | 0.2 ^b | 3.6 ^a |
| 20:4n-3 | 0.0 ^b | 0.6 ^a |
| 20:5n-3 | 0.1 ^b | 6.1 ^a |
| 22:5n-3 | 1.2 ^b | 5.8 ^a |
| 22:6n-3 | 1.0 ^a | 1.3 ^a |
| Total | 2.5 ^b | 17.4 ^a |
| n-6/n-3 Ratio | 14.7^a | 0.9^b |

Values are means of four measurements. Values for each fatty acid with the same letter do not differ significantly ($P < 0.01$) between control and fat-1.

Fig. 5




Fig. 4




Fig. 7




Fig. 8




Fig. 9

PUFA composition of total cellular lipids from the
 control rat cortical and the transgenic cells expressing a
C. elegans fat-1 cDNA

| Mol % of total fatty acids | Control | <i>fat-1</i> |
|-------------------------------|-------------|--------------|
| n-6 Polyunsaturates | | |
| 18:2n-6 | 1.78 | 0.87 |
| 20:4n-6 | 7.21 | 4.23 |
| 22:4n-6 | 1.57 | 0.72 |
| 22:5n-6 | 1.68 | 0.72 |
| Total | 12.26 | 6.53 |
| n-3 Polyunsaturates | | |
| 18:3n-3 | 0.34 | 0.86 |
| 20:5n-3 | 0.21 | 0.87 |
| 22:5n-3 | 0.29 | 0.81 |
| 22:6n-3 | 1.27 | 1.93 |
| Total | 2.11 | 4.48 |
| n-6/n-3 Ratio | 6.44 | 1.67 |

Values are means of four measurements. ($p < 0.01$) between control and *fat-1*.

Fig. 10




Fig. 11





Fig. 12

Ad.GFP



Ad.GFP.Fat-1




Fig.13




Fig. 14

PUFA composition of total cellular lipids from the
 control MCF-7 and the transgenic cells expressing a
C. elegans fat-1 cDNA

| Mol % of total fatty acids | Control | Fat-1 |
|-------------------------------|--------------------|-------------------|
| n-6 Polyunsaturates | | |
| 18:2n-6 | 3.13 ^a | 1.51 ^b |
| 20:2n-6 | 0.23 ^a | 0.22 ^a |
| 20:3n-6 | 0.34 ^a | 0.16 ^b |
| 20:4n-6 | 6.30 ^a | 2.26 ^b |
| 22:4n-6 | 0.53 ^a | 0.33 ^b |
| 22:5n-6 | 0.27 ^a | 0.11 ^b |
| Total | 10.80 ^a | 4.59 ^b |
| n-3 Polyunsaturates | | |
| 18:3n-3 | 0.0 ^b | 1.00 ^a |
| 20:4n-3 | 0.0 ^b | 0.10 ^a |
| 20:5n-3 | 0.0 ^b | 2.87 ^a |
| 22:5n-3 | 0.33 ^b | 1.47 ^a |
| 22:6n-3 | 0.60 ^a | 0.73 ^a |
| Total | 0.93 ^b | 6.17 ^b |
| n-6/n-3 Ratio | 11.61 ^a | 0.74 ^b |

Values are means of four measurements. Values for each fatty acid
 with the same letter do not differ significantly ($p < 0.01$) between
 control and fat-1.

Fig. 15




Fig. 16

Page 17 of 20
 MODIFIED FAT-1 NUCLEIC ACIDS, COMPOSITIONS AND METHODS FOR MODIFYING THE CONTENT OF
 POLYUNSATURATED FATTY ACIDS IN MAMMALIAN CELLS

Jing X. Kang
 00786-815P01

| | |
|--|-----|
| CAAGTTTGAG GT | 12 |
| ATG GTC GCT CAT TCC TCA GAA GGG TTA TCC GCC ACG GCT CCG GTC Met Val Ala His Ser Ser Glu Gly Leu Ser Ala Thr Ala Pro Val | 57 |
| 5 10 15 | |
| ACC GGC GGA GAT GTT CTG GTT GAT GCT CGT GCA TCT CTT GAA GAA Thr Gly Gly Asp Val Leu Val Asp Ala Arg Ala Ser Leu Glu Glu | 102 |
| 20 25 30 | |
| AAG GAG GCT CCA CGT GAT GTG AAT GCA AAC ACT AAA CAG GCC ACC Lys Glu Ala Pro Arg Asp Val Asn Ala Asn Thr Lys Gln Ala Thr | 147 |
| 35 40 45 | |
| ACT GAA GAG CCA CGC ATC CAA TTA CCA ACT GTG GAT GCT TTC CGT Thr Glu Glu Pro Arg Ile Gln Leu Pro Thr Val Asp Ala Phe Arg | 192 |
| 50 55 60 | |
| CGT GCA ATT CCA GCA CAC TGT TTC GAA AGA GAT CTC GTT AAA TCA Arg Ala Ile Pro Ala His Cys Phe Glu Arg Asp Leu Val Lys Ser | 237 |
| 65 70 75 | |
| ATC AGA TAT TTG CTG CAA GAC TTT GCG GCA CTC ACA ATT CTC TAC Ile Arg Tyr Leu Val Gln Asp Phe Ala Ala Leu Thr Ile Leu Tyr | 282 |
| 80 85 90 | |
| TTT GCT CTT CCA GCT TTT GAG TAC TTT GGA TTG TTT GGT TAC TTG Phe Ala Leu Pro Ala Phe Glu Tyr Phe Gly Leu Phe Gly Tyr Leu | 327 |
| 95 100 105 | |
| GTT TGG AAC ATT TTT ATG GGA GTT TTT GGA TTC GCG TTG TTC GTC Val Trp Asn Ile Phe Met Gly Val Phe Gly Phe Ala Leu Phe Val | 372 |
| 110 115 120 | |
| GTT GGA CAC GAT TGT CTT CAT GGA TCA TTC TCT GAT AAT CAG AAT Val Gly His Asp Cys Leu His Gly Ser Phe Ser Asp Asn Gln Asn | 417 |
| 125 130 135 | |
| CTC AAT GAT TTC ATT GGA CAT ATC GCC TTC TCA CCA CTC TTC TCT Leu Asn Asp Phe Ile Gly His Ile Ala Phe Ser Pro Leu Phe Ser | 462 |
| 140 145 150 | |
| CCA TAC TTC CCA TGG CAG AAA AGT CAC AAG CTT CAC CAT GCT TTC Pro Tyr Phe Pro Trp Gln Lys Ser His Lys Leu His His Ala Phe | 507 |
| 155 160 165 | |
| ACC AAC CAC ATT GAC AAA GAT CAT GGA CAC GTG TGG ATT CAG GAT Thr Asn His Ile Asp Lys Asp His Gly His Val Trp Ile Gln Asp | 552 |
| 170 175 180 | |
| AAG GAT TGG GAA GCA ATG CCA TCA TGG AAA AGA TGG TTC AAT CCA Lys Asp Trp Glu Ala Met Pro Ser Trp Lys Arg Trp Phe Asn Pro | 597 |
| 185 190 195 | |
| ATT CCA TTC TCT GGA TGG CTT AAA TGG TTC CCA GTG TAC ACT TTA Ile Pro Phe Ser Gly Trp Leu Lys Trp Phe Pro Val Tyr Thr Leu | 642 |
| 200 205 210 | |
| TTC GGT TTC TGT GAT GGA TCT CAC TTC TGG CCA TAC TCT TCA CTT | 687 |

Fig. 17A

| | | | |
|---|------|-----|-----|
| Phe Gly Phe Cys Asp Gly Ser His Phe Trp Pro Tyr Ser Ser Leu | 215 | 220 | 225 |
| TTT GTT CGT AAC TCT GAC CGT GTT CAA TGT GTA ATC TCT GGA ATC | 732 | | |
| Phe Val Arg Asn Ser Asp Arg Val Gln Cys Val Ile Ser Gly Ile | 230 | 235 | 240 |
| TGT TGC TGT GTG TGT GCA TAT ATT GCT CTA ACA ATT GCT GGA TCA | 777 | | |
| Cys Cys Cys Val Cys Ala Tyr Ile Ala Leu Thr Ile Ala Gly Ser | 245 | 250 | 255 |
| TAT TCC AAT TGG TTC TGG TAC TAT TGG GTT CCA CTT TCT TTC TTC | 822 | | |
| Tyr Ser Asn Trp Phe Trp Tyr Tyr Trp Val Pro Leu Ser Phe Phe | 260 | 265 | 270 |
| GGA TTG ATG CTC GTC ATT GTT ACC TAT TTG CAA CAT GTC GAT GAT | 867 | | |
| Gly Leu Met Leu Val Ile Val Thr Tyr Leu Gln His Val Asp Asp | 275 | 280 | 285 |
| GTC GCT GAG GTG TAC GAG GCT GAT GAA TGG AGC TTC GTC CGT GGA | 912 | | |
| Val Ala Glu Val Tyr Glu Ala Asp Glu Trp Ser Phe Val Arg Gly | 290 | 295 | 300 |
| CAA ACC CAA ACC ATC GAT CGT TAC TAT GGA CTC GGA TTG GAC ACA | 957 | | |
| Gln Thr Gln Thr Ile Asp Arg Tyr Tyr Gly Leu Gly Leu Asp Thr | 305 | 310 | 315 |
| ACG ATG CAC CAT ATC ACA GAC GGA CAC GTT GCC CAT CAC TTC TTC | 1062 | | |
| Thr Met His His Ile Thr Asp Gly His Val Ala His His Phe Phe | 320 | 325 | 330 |
| AAC AAA ATC CCA CAT TAC CAT CTC ATC GAA GCA ACC GAA GGT GTC | 1047 | | |
| Asn Lys Ile Pro His Tyr His Leu Ile Glu Ala Thr Glu Gly Val | 335 | 340 | 345 |
| AAA AAG GTC TTG GAG CCG TTG TCC GAC ACC CAA TAC GGG TAC AAA | 1092 | | |
| Lys Lys Val Leu Glu Pro Leu Ser Asp Thr Gln Tyr Gly Tyr Lys | 350 | 355 | 360 |
| TCT CAA GTG AAC TAC GAT TTC TTT GCC CGT TTC CTG TGG TTC AAC | 1137 | | |
| Ser Gln Val Asn Tyr Asp Phe Phe Ala Arg Phe Leu Trp Phe Asn | 365 | 370 | 375 |
| TAC AAG CTC GAC TAT CTC GTT CAC AAG ACC GCC GGA ATC ATG CAA | 1182 | | |
| Tyr Lys Leu Asp Tyr Leu Val His Lys Thr Ala Gly Ile Met Gln | 380 | 385 | 390 |
| TTC CGA ACA ACT CTC GAG GAG AAG GCA AAG GCC AAG TAA | 1221 | | |
| Phe Arg Thr Thr Leu Glu Glu Lys Ala Lys Ala Lys | 395 | 400 | |
| AAGAATATCC CGTGCCGTTC TAGAGTACAA CAACAACCTC TGC GTTTTCA | 1271 | | |
| CCGGTTTTGC TCTAATTGCA ATTTTCTTT GTTCTATATA TATTTTTTG | 1321 | | |
| CTTTTAAAT TTATTCTCTC TAAAAAAGCTT CTACTTTTCA GTGCGTTGAA | 1371 | | |
| TGCATAAAGC CATAACTCTT | 1391 | | |

Fig. 17B

Optimized *fat-1* Sequence:

1. caa gtt tga ggt ATG gtc gct cat tcc AGC gaa ggg CtG tcc gcc acg gct ccg gtc acc
 61. ggc ggC gat gtG ctg gtG gat gcC cgt gca tct ctG gaG gaG aag gag gcC ccC cgC gaC
 121. gtg aat gca aac act aaa cag gcc acc act gaG gag ccC cgc atc caG tta ccC act gtg
 181. gat gcC ttc cgC cgC gca att ccC gca cac tgC ttc gaG agG gaC ctc gtG aaa tca atc
 241. agG tat CtG gtg caG gac ttt gcg gca ctG aca att ctG tac ttt gcC ctt ccC gcC ttt
 301. gag tac ttt ggC CtG ttt ggt tac CtG gtG tgg aac att ttt atg ggC gtt ttt ggC ttc
 361. gcg CtG ttc gtc gtt gga cac gaC tgt ctt caC ggC tca ttc tcC gat aat cag aat ctc
 421. aat gat ttc att gga cat atc gcc ttc AGC cca ctc ttc tct ccC tac ttc ccC tgg cag
 481. aaa agt cac aag ctG cac caC gcC ttc acc aac cac atC gac aaa gat cat gga cac gtg
 541. tgg atA cag gat aag gat tgg gaa gca atg ccC AGC tgg aaa aga tgg ttc aat ccT att
 601. ccT ttc tct ggC tgg ctG aaa tgg ttc ccT gtg tac act CtG ttc ggt ttc tgC gat gga
 661. tcC cac ttc tgg ccT tac tcC tca ctG ttt gtG cgC aac tct gaa cgC gtt caG tgt gta
 721. atc tct gga atc tgC tgc tgt gtg tgC gca tat att gct cta aca att gct gga AGC tat
 781. tcc aat tgg ttc tgg tac tat tgg gtt cca ctt tct ttc ttc ggC ttg atg ctc gtc att
 841. gtt acc tat CtG caG caC gtc gaC gaC gtc gct gag gtg tac gag gct gat gaa tgg agc
 901. ttc gtc cgG gga caG acc caG acc atc gat cgt tac tat ggC ctc ggC ttg gac aca acg
 961. atg cac cat atc aca gac gga cac gtt gcc caC cac ttc ttc aac aaa atc cca cat tac
 1021. cat ctc atc gaa gca acc gaa ggt gtc aaa aag gtc ttg gag ccg ttg tcc gac acc caa
 1081. tac ggg tac aaa tct caG gtg aac tac gat ttc ttt gcc cgG ttc ctg tgg ttc aac tac
 1141. aag ctc gac tat ctc gtt cac aag acc gcc gga atc atg caa ttc cga aca act ctc gag
 1201. gag aag gca aag gcc aag tG aag aat atc ccg tgc cgt tct aga gta caa caa caa ctt
 1261. ctg cgt ttt cac cgg ttt tgc tct aat tgc aat ttt tct ttg ttc tat ata tat ttt ttt
 1321. gct ttt taa ttt tat tct ctc taa aaa act tct act ttt cag tgc gtt gaa tgc ata aag
 1381. cca taa ctc tt

Fig. 18




Fig. 19